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ABSTRACT

The very potent antibacterial activity of cecropin B makes it a likely candidate to
prevent and/or treat Mannheimia haemolytica 1:A infection in the upper respiratory tract
(URT) of cattle. The purpose of this study was to ascertain if the URT could be
transfected with a gene coding for the antimicrobial peptide cecropin B. By transfecting
cattle with a gene coding for cecropin B, this study attempted to inhibit colonization of a
virulent strain of M. haemolytica 1:A in the URT while investigating any possible
changes in the indigenous and transient nasal flora.
In this study the antibacterial efficacy of cecropin B for a virulent strain of M.
haemolytica 1:A was determined. In vitro results showed that cecropin B was very
effective in inhibiting this virulent strain of M. haemolytica 1:A within 20 minutes of
incubation at 37°C. No inhibition of its activity was observed by incubating cecropin B
in pooled bovine nasal secretions.
The nasal passages of calves were aerosolized with different amounts of plasmid
DNA containing a gene coding for cecropin B. Results of this study show that calves
transfected with 50 or 100 µg of plasmid DNA per nostril were able to express cecropin
B at the mRNA and peptide level. Detection of the cecropin B gene in control calves
may indicate the possibility of native bovine cecropin.
After challenge with a virulent strain of M. haemolytica 1:A, all calves were stressed by
transportation in a crowded trailer 100 miles for 3 hours. Seven out of the 8 control
calves yielded detectible levels of M. haemolytica 1:A in nasal aspirates throughout the
weeks following challenge. All 4 calves given 25 µg of plasmid DNA per nostril and two
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of the 4 calves given 50 µg of plasmid DNA per nostril yielded detectible levels of M.
haemolytica 1:A in nasal aspirates following challenge. However, M. haemolytica 1:A
was not detected in any calf given 100 µg of plasmid DNA per nostril. There appeared to
be no change in the normal bacterial nasal flora.
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INTRODUCTION

The disease known as pneumonic pasteurellosis was first described in cattle
during the late 1800’s (Mosier et al., 1989). Prevalence in the stockyards after shipment
has earned this disease the common name ‘shipping fever’. Today ‘shipping fever’
continues to be responsible for major economic losses in the North American beef cattle
industry. More than a billion dollars are lost annually due to clinical disease and death in
feedlot cattle (Brennan et al., 1998, Confer et al., 1994). Pneumonic pasteurellosis is
multifactorial and complex, with stress and other environmental factors contributing to
pathogenesis of the disease (Mosier et al., 1989). However, it is believed that a bacterium
commonly isolated from the nasal passages of healthy cattle is a major cause of
pasteurellosis (Biberstein et al., 1960). Mannheimia haemolytica 1:A (formerly
Pasteurella haemolytica 1:A) produces the fibrinous pneumonia associated with the
disease (Mosier et al., 1989), and is termed the major etiologic agent of bovine
pneumonic pasteurellosis (Dalgleish, 1990, Frank, 1986).
While M. haemolytica serotype 1:A is the Gram-negative bacterium generally
regarded as the cause of bovine pleuropneumonia it can be a normal resident of the
bovine nasal tract. Under times of stress, M. haemolytica 1:A proliferates in the upper
respiratory tract (URT). Stressors include transportation, crowding, irregular feeding or
watering, abrupt climate change, and exposure to viral agents or a combination of the
above (Frank et al., 1986, Yates, 1982). Stress induced proliferation of M. haemolytica
1:A following transportation is most likely the cause of pneumonic pasteurellosis in
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stockyards (Frank et al., 1986, Yates, 1982). Treatment within 24 hours of shipment may
be important for the protection of these cattle.
Vaccines which provide cattle with consistent immunity to pneumonic
pasteurellosis are not yet available. Knowledge of M. haemolytica’s virulence factors
and the host immune response is necessary for the development of effective vaccines.
Data obtained from aerosol vaccination of 205 kg calves has shown that aerosol
vaccination at the level of the middle meatus enhances M. haemolytica 1:A clearance
from the nasal passage and prevents migration of M. haemolytica 1:A to the lung, while
vaccination at the level of the tracheal bifurcation does not affect nasal colonization of M.
haemolytica (Brennan et al., 1998). Furthermore, vaccination at the level of the middle
meatus results in the production of IgA type antibodies to various M. haemolytica whole
cell and outer membrane antigens which can be detected in nasal secretions (Brennan et
al., 1998). These studies indicate the importance of stimulating immunity to pneumonic
pasteurellosis in the URT.
Since vaccines which provide cattle with consistent immunity to pneumonic
pasteurellosis are not yet available, most veterinarians rely on antimicrobial agents to
treat the disease. Streptomycin, tetracyclines, β-lactam antibiotics, chloramphenicol,
sulfonamides, and trimethoprim-sulfonamide combinations have all been used to treat
pneumonic pasteurellosis. Studies have shown M. haemolytica 1:A to have an increasing
pattern of resistance to all of these antimicrobial agents (Hartman et al., 1993).
Public concern for the use of antibiotics in food is once again gaining momentum.
Although the use of antibiotics may result in significantly harmful residue levels in food
meant for human consumption, these illegal drug residues are no longer being found in
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carcasses. The concern has now shifted to drug-resistant microbes. Many producers use
low doses of antibiotics as growth promoters (Ferber, 2003). The result is an increased
occurrence of antibiotic resistant bacteria, which may pose a threat to human health
(Ferber, 2003). An effort to eliminate the routine use of antibiotics in food animal
production is underway (Ferber, 2003). It may be beneficial to find novel antimicrobials
to prevent and/or treat infection.
The Cecropia moth, Hyalophora cecropia, responds to bacterial infection with
very effective antibacterial activity. The pupae synthesize several different classes of
antibacterial proteins (Van Hofsten et al., 1985, Xanthopoulos et al., 1988). The most
potent of these are the cecropins, specifically cecropins A, B, C, D, E, and F (Boman et
al., 1987). Cecropins are small strongly basic proteins which have a broad spectrum of
bactericidal activity (Steiner et al., 1988), but are unable to disrupt eukaryotic cells
(Boman et al., 1991). This clearly implicates their possible usefulness as novel
antibiotics. Although the exact mechanisms are not fully understood, cecropins have been
shown to have direct action on bacterial membranes (Steiner et al., 1988). Determining
the structure of the two cecropin homologues has revealed structural elements common
among membrane-associated proteins (Steiner et al., 1988). Primary membrane attack is
considered to be the cause of both Gram-positive and Gram-negative bacteria lysis
(Steiner et al., 1988). Furthermore, binding sufficient amounts of cecropin to form a
monolayer is necessary to modify the bacterial membranes.
It is believed that to provide protection against pneumonic pasteurellosis, M.
haemolytica 1:A should not be allowed to colonize the URT. The antibacterial activity of
cecropin B against M. haemolytica 1:A has not been reported previously. Cecropin B has
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been shown to possess the broadest bactericidal activity of the cecropin family (Chen et
al., 1997). It may be useful for eradication of pathogens from mucosal surfaces because
it is highly effective against Gram-negative bacteria (Vaara et al., 1994). Cecropin B not
only has the ability to effectively inhibit bacterial colonization, but it also neutralizes
endotoxin. The very potent broad spectrum antibacterial activity of cecropin B makes it a
likely candidate to prevent and/or treat infection. However, cost of production may limit
this peptide’s practical uses. The most cost-efficient peptide synthesis methods employed
at the present time are still unreasonable (Hancock et al., 1998). One possible costeffective approach would be to transfer the cecropin B gene into the species of interest
and let the recipient’s biosynthesis mechanisms synthesize the peptide. Although there
are many indications that a transgenic or gene therapeutic approach may be useful in
enhancing bacterial resistance in food animals, thereby reducing the use of conventional
antibiotics, very few studies are available describing transfected mammals expressing
cecropin B or cecropin B-like peptides.
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CHAPTER 1
LITERATURE REVIEW

Classification, Economic Impact, and Habitat
The Bovine Respiratory Disease (BRD) Complex can be summarized as three
major entities (Lillie, 1974). Clinically, these entities are known as enzootic pneumonia
of calves, atypical interstitial pneumonia, and pneumonic pasteurellosis. Pneumonic
pasteurellosis, commonly known as “shipping fever” was first described over a century
ago (Mosier et al., 1989). Since then many aspects of the disease have been thoroughly
investigated. Despite the extensive amount of research on pneumonic pasteurellosis, its
continued prevalence in the feedlots is responsible for major economic losses in the
North American beef cattle industry. More than a billion dollars are lost annually due to
clinical disease in feedlot cattle (Brennan et al., 1998, Confer et al., 1994). Calves
diagnosed with clinical pneumonic pasteurellosis experience increased weight loss during
shipment, lower average daily gains, and poorer carcass quality. The disease is complex
and multifactorial (Mosier et al., 1989). However one bacterium is most frequently
associated with the disease (Biberstein et al., 1960). The major etiologic agent of bovine
pneumonic pasteurellosis is Mannheimia haemolytica 1:A (Dalgleish, 1990, Frank,
1986). M. haemolytica 1:A (formally known as Pasteurella haemolytica 1:A) is a
nonmotile, Gram-negative coccobacillus or rod, and a facultative anaerobe. M.
haemolytica 1:A expresses many virulence factors which help to facilitate disease. These
components include capsular polysaccharide, lipopolysaccharide (LPS) also known as
endotoxin, and leukotoxin (Conlon et al., 1991, Whiteley et al., 1992). Other virulence
factors may include outer membrane proteins (OMPs), a sialoglycoprotease, a
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neuraminidase and possibly two types of fimbriae (Brennan et al., 1997, Lee et al., 1994,
Whiteley et al., 1992).
M. haemolytica 1:A is considered to be part of the normal bacterial flora in the
upper respiratory tract (URT) of healthy cattle, and can exist in the nasal cavity in very
low numbers (Carter et al., 1991, Whiteley et al., 1992). It is believed that healthy cattle
can carry undetectable levels of M. haemolytica 1:A for long periods of time (Frank,
1988). After shipment or other forms of stress, cattle may shed larger numbers of the
bacterium (Frank et al., 1986). Furthermore, M. haemolytica 1:A is likely carried in one
or more sites distinct from the nasal cavity, specifically the palatine tonsils (Frank et al.,
1992). The tonsils provide an ideal site for carrying the bacterium due to their location
(Frank et al., 1992, Lillie et al., 1974). The use a rifampicin-resistant strain of M.
haemolytica 1:A allowed researchers to show that the organism colonized the tonsils and
nasal cavity for more than two weeks in experimentally infected calves and commingled
calves (Briggs et al., 1998). Tonsilar localization of M. haemolytica 1:A in healthy cattle
allows for stress induced colonization of the nasal cavity and shedding of the organism.
The Normal and Transient Flora of the Bovine Nasal Passage
In addition to M. haemolytica, Pasteurella multocida and Haemophilus somnus,
other bacteria commonly associated with BRD, the nasal passage of cattle is home to a
diverse collection of bacteria that make up the normal and transient flora. Although a
complete listing of all the bacteria found in the nasal passage of cattle does not appear to
have been reviewed recently, the list of organisms cited in the literature is extensive.
Some of the more frequently isolated bacteria from the URT include Gram-positive
bacteria such as Micrococcus, Corynebacterium, Staphylococcus, Streptococcus, and
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Bacillus as well as Gram-negative bacteria such as Pseudomonas, Actinobacter,
Moraxella, Neisseria catarrhalis, and Escherichia coli (Corbeil et al., 1985, Woldehiwet
et al., 1990). Other members of the bovine nasal flora may include Gram-positive
bacteria such as Lactobacillus, Streptomyces, and Diplococcus pneumoniae as well as
Gram-negative bacteria such as Chromobacterium, Achromobacter, Serratia,
Flavobacterium, Proteus, and Klebsiella (Magwood et al., 1969). These species of
bacteria have been found to start colonizing the URT as early as the calf’s first day of life
(Woldehiwet et al., 1990). The total bacterial load in the nasal passage increases with
age, and is influenced by environmental temperature (Woldehiwet et al., 1990). Studies
have shown that the population of bacteria in the nasal passage of calves fluctuates
heavily in types and numbers (Magwood et al., 1969, Woldehiwet et al., 1990).
Sometimes one genus or species is more dominant than others for random periods of
time. As early as 1969 it was shown that M. haemolytica was capable of outnumbering
the rest of the nasal flora for several days at a time (Magwood et al., 1969).
These bacteria, considered normal and transient nasal flora, may enhance or
inhibit growth of M. haemolytica. Bacillus isolates were found to inhibit the growth of
M. haemolytica in vitro (Corbeil et al., 1985). In contrast, several Gram-positive bacteria
such as Micrococcus, Corynebacterium, and Staphylococcus were found to efficiently
enhance the growth of M. haemolytica in vitro (Corbeil et al., 1985). The two Gramnegative bacteria Moraxella and Actinobacter enhanced M. haemolytica growth in vitro
as well (Corbeil et al., 1985). Corbeil et al. showed that the normal and transient flora of
the nasal passage can significantly affect the colonization of M. haemolytica 1:A.
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Pathogenesis
Remaining in the URT of unstressed cattle, M. haemolytica 1:A causes no disease
in the animal (Lillie, 1974). Under times of stress in the form of transportation,
crowding, irregular feeding or watering, abrupt climate change, exposure to viral agents,
or combination of the above, M. haemolytica 1:A proliferates in the URT (Frank et al.,
1986, Yates, 1982). Stress also disrupts M. haemolytica 1:A localization, and allows the
bacterium to colonize other parts of the respiratory tract. Conditions such as stress or cell
damage and inflammation are ideal for M. haemolytica 1:A colonization and proliferation
in the URT. Stressed cattle shed large numbers of M. haemolytica 1:A, which can be
isolated during and immediately after shipment (Frank et al., 1986). Increased
colonization and proliferation of M. haemolytica 1:A in the URT allows the organism to
be inhaled into the lung (Frank, 1988). Researchers have shown that M. haemolytica 1:A
can be isolated from droplet nuclei in tracheal air (Whiteley et al., 1992). In the lower
respiratory tract (LRT), M. haemolytica 1:A would be easily cleared and no lung damage
would occur under normal conditions (Shewen et al., 1982). However, chronic exposure
to the lung allows M. haemolytica 1:A to overcome clearance mechanisms and to initiate
pneumonia (Frank, 1988). Intranasal and intratracheal inoculation of M. haemolytica
1:A, as well as transthoracic inoculation of M. haemolytica 1:A directly into the lung
have been shown to produce pneumonic lung lesions (Frank, 1986).
The respiratory tract immune system operates separately from the systemic
immune system (McBride et al., 1996, McBride et al., 1999). In addition, the immune
response in the upper URT differs significantly from the immune response in the LRT
(Brennan et al., 1997). The immune response in the URT is specific, and not associated
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with damage to the URT. While the immune response in the URT either prevents or
controls M. haemolytica 1:A colonization, the immune response elicited by the organism
in the LRT may cause the damage recognized clinically as fibrinous pleuropneumonia.
The host immune response in the LRT is highly associated with acute pneumonic
pasteurellosis (McBride et al., 1999). Chronic exposure to M. haemolytica 1:A in the
lung induces inflammation, involving the influx of neutrophils and macrophages,
extensive fibrin exudation, and enhanced vascular permeability (Whiteley et al., 1992,
Yates, 1982). Inflammation and exudate as a result of the host immune response allows
M. haemolytica 1:A to colonize the induced lesion by hindering clearance and providing
an excellent iron-rich medium. M. haemolytica 1:A colonization in the lung and
immune-mediated damage contribute heavily to the pathogenesis of pneumonic
pasteurellosis. Histopathologic examinations of lung lesions reveal M. haemolytica 1:A
and degrading inflammatory cells surrounding a foci of coagulation necrosis (Whiteley et
al., 1992, Yates, 1982). Calves depleted of neutrophils have been shown to be somewhat
resistant to lung lesion development (McBride et al., 1999). It is believed that
neutrophils may be the primary effector of the disease. Neutrophils can be detected in
lung lavage fluids within hours after M. haemolytica 1:A inoculation (McBride et al.,
1999).
Leukotoxin and endotoxin secreted by M. haemolytica 1:A may also elicit an
inflammatory response (Shewen et al., 1982). Using a neutrophil mediated pathway,
leukotoxin damages primary endothelial cells, and kills neutrophils and alveolar
macrophages (Frank et al., 1986, McBride et al., 1999). Killing neutrophils in the lung
contributes to the early formation of lesions (Frank, 1986). The tissue destruction that
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can lead to lesion formation is ultimately a result of the release of toxic oxygen radicals
and proteases from neutrophils (Whiteley et al., 1991). Endotoxin directly interacts with
the alveolar and pulmonary intravascular macrophages, causing them to synthesize
proinflammatory cytokines TNFα, IL1, IL8, procoagulents, proteases and toxic oxygen
radicals (Whiteley et al., 1991). It has been shown that endotoxin alone can initiate an
inflammatory response in the lung (Whiteley et al., 1991).
One study suggests that immune complex disease (type III hypersensitivity)
contributes to the development of the host inflammatory response (McBride et al., 1999),
and that pneumonic pasteurellosis is in part an allergic pneumonitis. A Type III
hypersensitivity to M. haemolytica 1:A antigens activates complement resulting in
inflammation and neutrophilic influx. However, evidence suggests that M. haemolytica
1:A colonization in the lung and immune-mediated damage, including a type III
hypersensitivity both play a role in the pathogenesis of bovine pneumonic pasteurellosis.
Vaccination Attempts
Vaccines which provide cattle with consistent immunity to pneumonic
pasteurellosis are not yet available. Bacterins, combined bacterins, live, modified-live,
viral, and component vaccines have been developed to protect cattle from shipping fever
(Mosier et al., 1989). Most elicit some protection; however none of the bacterial
immunogens have been able to consistently protect cattle in the field. M. haemolytica
1:A bacterins have been shown to be ineffective (Frank, 1986) and sometimes harmful.
One belief is that the bacterins do not elicit antibody responses to the antigens important
to pathogenesis (Frank, 1986). Researchers found that serum antibody titers correlated
directly with resistance to lung challenge (Confer et al., 1983); however another
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explanation for the failure of bacterins in the field is that they produce an IgG response
(Frank, 1986, Mosier et al., 1989). Neutrophils phagocytize M. haemolytica 1:A
opsonized by IgG, and in turn the neutrophils are killed by leukotoxin released by M.
haemolytica 1:A (Frank, 1986). The result is immune-mediated lesion development.
Since viral infections were associated with M. haemolytica 1:A colonization in the
lung, many viral vaccines have been developed (Mosier et al., 1989). Although
vaccination of cattle against Parainfluenza 3 (PI3) and Infectious Bovine Rhinotracheitis
virus (IBRV) provided resistance to pneumonic pasteurellosis caused by M. haemolytica
1:A challenge under laboratory conditions (Frank, 1986), field trials of the vaccines were
unable to provide cattle with protection (Mosier et al., 1989). Vaccination for Bovine
Viral Diarrhea Virus (BVDV) was also targeted, however, as with the other viral
vaccines failure in field experiments was attributed to the wide range of viruses that can
elicit pneumonic pasteurellosis (Mosier et al., 1989). In addition cattle vaccinated with
viral vaccines were still susceptible to M. haemolytica 1:A. In the next logical step,
vaccines which combined M. haemolytica 1:A and viral antigens were developed. As
with viral vaccines, combination vaccines provided cattle with protection under
laboratory conditions, but failed in field experiments (Mosier et al., 1989). They also
have the potential, like bacterins, to be more harmful.
Recombinant leukotoxin (rLKT) vaccines also met with little success (Conlon et
al., 1991). Inoculating cattle with a rLKT vaccine did enhance the efficacy of another
vaccine and decrease clinical signs as well as lung lesions; yet an immune response to
leukotoxin alone did not protect cattle against pneumonic pasteurellosis (Conlon et al.,
1991). Leukotoxin does play an important role in the pathogenesis of the disease, but
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pneumonic pasteurellosis is multifactorial and complex. Other studies have shown that
vaccination with various surface antigens such as LPS (endotoxin) and purified capsular
polysaccharide also failed to protect cattle from pneumonic pasteurellosis (Confer et al.,
1994).
Live and modified-live vaccines have been shown to be more effective in
protecting cattle than any other type of vaccine (Mosier et al., 1989). Studies have shown
live M. haemolytica 1:A vaccines to enhance resistance to experimental challenge
(Confer et al., 1985). Although live and modified-live vaccines have been more effective
at eliciting an immune response, they are still not consistent in field experiments. Most
vaccines developed thus far have been able to produce some immune response.
However, previously developed vaccines all have failed to provide cattle with consistent
resistance to M. haemolytica 1:A and pneumonic pasteurellosis in the field.
Antibiotic Therapy
The use of antibiotics to treat pneumonic pasteurellosis has been generally
successful (Frank, 1986). Antibiotics are chemical substances of microbial origin. They
can either destroy or inhibit the growth of bacteria. Antibiotics such as tetracyclines and
sulfonamides have a broad spectrum of activity against a wide range of bacteria, while
antibiotics such as fluoroquinolones have a narrow spectrum of activity. Antibiotics have
four mechanisms of action. They may inhibit cell wall synthesis, cell wall function,
nucleic acid synthesis, or protein synthesis. In the past, antibiotics were purified from
media filtrates. Later they were synthesized. Today new antibiotic drugs are
biosynthesized from chemical modification of molecules.
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Most veterinarians rely on antimicrobial agents to treat pneumonic pasteurellosis.
Antimicrobial therapy is a very effective method for both the treatment and prevention of
BRD (Watts et al., 1994). The veterinarian may select antibiotics for treatment on the
basis of perceived efficacy, cost, convenience, availability, toxicity, and residue profile
(Watts et al., 1994). Veterinary diagnostic labs assist the veterinarian by performing
susceptibility tests and providing consistent interpretations of the results (Shyrock et al.,
1996). By monitoring the susceptibility trends of M. haemolytica 1:A, veterinarians can
select the most effective antibiotics. With the occurrence of antibiotic resistant strains of
bacteria, the appropriate use of antibiotics should include exposing M. haemolytica 1:A
to sufficient concentrations of the antimicrobial agents for an appropriate duration as to
minimize the development of resistant strains (Watts et al., 1994).
β-lactam antibiotics such as ampicillin, which inhibit bacterial cell wall synthesis
have been used to treat pneumonic pasteurellosis in the past. However, ampicillin
resistant strains of M. haemolytica 1:A have been frequently encountered (Hartman et al.,
1993, Watts et al., 1994). A relatively new β-lactam antibiotic, ceftiofur, which is a
cephalosporin with an extended spectrum of activity, was shown to be very effective
against M. haemolytica 1:A (Watts et al., 1994). Using a M. haemolytica 1:A challenge
model researchers were able to show that a single subcutaneous injection of ceftiofur
crystalline-free acid sterile oil suspension (CCFA-SS, 100 mg ceftiofur equivalents
(CE)/ml) of 4.4 to 8.8 CE/kg of body weight was very effective at inhibiting colonization
in the lung (Hibbard et al., 2002). The formulation was long-acting and more effective
than tilmicosin, though alternative sites for injection must be found because subcutaneous
injections in the neck left ceftiofur residues for extended periods of time (Hibbard et al.,
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2002). In a four year survey to monitor the emergence of antibiotic resistant strains of M.
haemolytica 1:A no strains were found to be resistant to ceftiofur (Watts et al., 1994).
Antibiotics which inhibit bacterial nucleic acid synthesis such as sulfonamides
and sulfonamide-trimethoprim combinations have been used to treat pneumonic
pasteurellosis in the past as well (Watts et al., 1994). Studies have shown M. haemolytica
1:A to have an increasing pattern of resistance to these antibiotics (Hartman et al., 1993).
It has been speculated that resistance to sulfamethazine is so widespread that its
usefulness in cattle is limited (Watts et al., 1994). Flouroquinolones including
ciprofloxacin, norfloxacin, and enrofloxacin are entirely man made antibiotics, which
have remarkable potency against many aerobic and facultative anaerobic bacteria
(Prescott et al., 1990). All three antibiotics were shown to have a minimum inhibitory
concentration (MIC) of less than or equal to 0.06 µg/ml for 100% of the M. haemolytica
1:A isolates tested in vitro (Prescott et al., 1990). Enrofloxacin, which is approved for
use in cattle, was shown to have a 0.03 µg/ml MIC for 100% of the M. haemolytica 1:A
isolates tested (Prescott et al., 1990).
Streptomycin, tetracyclines, spectinomycin, chloramphenicol, erythromycin,
florfenicol, and tilmicosin all inhibit bacterial protein synthesis. Streptomycin,
tetracyclines, spectinomycin, chloramphenicol and erythromycin resistant strains of M.
haemolytica 1:A have been frequently encountered ( Hartman et al., 1993, Watts et al.,
1994). In a four year survey to monitor the emergence of antibiotic resistant strains of M.
haemolytica 1:A, tetracycline and spectinomycin were shown to have MICs of 32 µg/ml
and 64 µg/ml respectively to 90% of the isolates tested (Watts et al., 1994).
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Administering florfenicol to cattle upon arrival at a stockyard was shown to
decrease the detection of M. haemolytica 1:A in the nasopharynx (Frank et al., 2002).
Tilmicosin is a relatively new macrolide antibiotic, with mostly anti-Gram-positive
bacterial activity. However, this macrolide can inhibit some Gram-negative organisms
including Mannheimia, Pasteurella, Haemophilus and Actinobacillus bacteria (Shyrock
et al., 1996). In vitro studies have shown tilmicosin to have significant antibacterial
activity against M. haemolytica 1:A (Hartman et al., 1993). Tilmicosin was shown to
have an MIC of less than or equal to 2 µg/ml for 96% of the M. haemolytica 1:A isolates
tested (Hartman et al., 1993). However, in the four year survey to monitor the emergence
of antibiotic resistant strains of M. haemolytica 1:A, tilmicosin effectiveness was found to
vary substantially (Watts et al., 1994). Due to increased resistance to erythromycin,
another macrolide, the usefulness of tilmicosin in the treatment of and protection from
pneumonic pasteurellosis may decrease (Watts et al., 1994).
Public concern for the use of antibiotics in food animals is once again gaining
momentum. Although the use of antibiotics may result in significantly harmful residue
levels in food meant for human consumption, these illegal drug residues are no longer
being found in carcasses. The U.S. Department of Agriculture’s (USDA) Food Safety
and Inspection Service (FSIS) ensure that antibiotic residues in food products are within
established limits. The concern has now shifted to drug-resistant microbes. Many
producers use low doses of antibiotics as growth promoters (Ferber, 2003). The result is
an increased occurrence of antibiotic resistant bacteria, which may pose a threat to human
health (Ferber, 2003). An effort to eliminate the routine use of antibiotics in food animal
production is underway (Ferber, 2003). In 1996, the U.S Food and Drug Administration
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(FDA), U.S. Centers for Disease Control and Prevention (CDC), and USDA began
coordinating under the National Antimicrobial Resistance Monitoring System’s
(NARMS) Enteric Bacteria program in an effort to provide objective information and
analysis about trends of antibiotic resistance in animal bacteria due to agricultural
practices.
Preventing Colonization of the Nasal Passage
The immune response in the URT differs significantly from the immune response
in the LRT (Brennan et al., 1997). While the immune response in the URT either
prevents or controls M. haemolytica 1:A colonization, the immune response elicited in
the LRT may cause damage. The immunoglobulin A (IgA) comprises 90% of the
antibody present in the URT (McBride et al., 1996). This is much greater than in the
LRT. In one study, IgA was not detected at all in lung lavage fluids of cattle receiving
intrapulmonary inoculations of M. haemolytica 1:A (McBride et al., 1999). Although
IgA is present in the LRT, IgG1 is the most dominant antibody in the lung (Brennan et al.,
1997). Both IgG1 and IgA have been associated with enhanced M. haemolytica 1:A
clearance in the lung (McBride et al., 1996). However both immunoglobulins have also
been implicated in contributing to the inflammatory response leading to acute lung
lesions (Frank, 1986, Johnson et al., 1986).
In the nasopharynx, IgA and a portion of the IgG1 are locally produced (Duncan
et al., 1972). By reducing the ability of bacteria to invade mucosal surfaces, IgA is
believed to be the first line of defense against M. haemolytica 1:A colonization in the
URT (Roth, 1991). Since critical numbers of M. haemolytica 1:A must be aspirated into
the lung to cause pneumonic pasteurellosis (Frank, 1988), reducing the levels of M.
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haemolytica 1:A colonization in the nasopharynx would provide cattle with protection
against the disease. If IgA antibodies could reduce M. haemolytica 1:A colonization in
the nasopharynx, then finding ways to induce a secretory IgA response on the mucosal
surfaces in the nasal cavity are paramount. When attempting to induce mucosal
immunity, the route of vaccine administration is important (Roth, 1991). Administering
the vaccine intranasally is beneficial when trying to induce a secretory IgA response.
Studies have shown that intranasal vaccination can play a key role in inducing an immune
response to M. haemolytica 1:A in the nasopharynx (Brennan et al., 1998). Aerosol
vaccination at the level of the middle meatus in the nasal cavity of cattle was shown to
enhance M. haemolytica 1:A clearance from the nasopharynx and prevented migration of
M. haemolytica 1:A into the lung (Brennan et al., 1998). Immunoglobulin A antibodies
were detected in the nasal secretions of these cattle. This evidence supports a previous
study in which researchers trying to colonize the nasal passages of cattle found that after
rapid clearance of M. haemolytica 1:A, the calves responded with antibody titers
detectable in nasal secretions (Frank, 1988). However the use of currently available
vaccines does not allow enough time for an effective immune response to develop before
the onset of pneumonic pasteurellosis in calves at the feedlots (Frank et al., 2002).
It appears there have been very few studies aimed at the use of antibiotics to
eliminate colonization of the nasal passage. The use of an effective antibiotic to inhibit
the rapid colonization of M. haemolytica 1:A in the nasopharynx should reduce the
occurrence of pneumonic pasteurellosis in cattle arriving at the feedlots. The use of
oxytetracycline or the feeding chlortetracycline at the feedlots did not reduce or eliminate
the colonization of M. haemolytica 1:A in the nasopharynx (Frank et al., 2000b). In
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calves experimentally infected with M. haemolytica 1:A, tilmicosin was effective in
alleviating clinical signs and pathology findings of pneumonic pasteurellosis as well as
the presence of viable organisms in the lung (Morck et al., 1997). Furthermore, a single
subcutaneous injection of 10mg per kg body weight protected the lung for up to 72 hours
with concentrations well above the MIC for M. haemolytica 1:A (Morck et al., 1997).
Researchers have also shown that a single dose of 10 mg per kg body weight of
tilmicosin was more effective at reducing mortality due to pneumonic pasteurellosis than
ceftiofur, oxytetracycline, or trimethoprim-sulfadoxine (Shyrock et al., 1996). In a study
focused on decreasing M. haemolytica 1:A colonization in the nasopharynx, both
florfenicol and tilmicosin were shown to be effective (Frank et al., 2000a, Frank et al.,
2002). Florfenicol inhibited M. haemolytica 1:A colonization in the nasal passage for up
to 4 days, while tilmicosin inhibited M. haemolytica 1:A colonization in the nasal passage
for up to 6 days (Frank et al., 2002). There appears to be no advantage to using
tilmicosin before or after arrival at the stockyard (Frank et al., 2000b). Using an
antibiotic such as tilmicosin before or after transport can reduce the occurrence of
pneumonic pasteurellosis at the stockyards, and would also allow vaccines given before
transport time to elicit an immune response (Frank et al., 2000b).
Clinical pneumonic pasteurellosis seems inevitable only after M. haemolytica 1:A
colonization and proliferation occurs in the URT. Preventing M. haemolytica 1:A from
ever colonizing the nasopharynx of cattle would certainly be ideal, although unrealistic.
Simply controlling the prolific growth of M. haemolytica 1:A by antimicrobial treatment
or by eliciting an antibody response in the nasal passage would reduce the number of
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organisms reaching the lungs. Reduced numbers of bacteria in the LRT would be easily
cleared with no lung damage, thereby preventing pneumonia before it is started.
Insect Immunity
Insects, like vertebrates, respond to infection with a highly effective immune
system, both cellular and humoral (Boman et al., 1991). Although lymphocytes have
never been found in insects, and they were once thought not to possess any form of
immunoglobulins, these invertebrates still have a specialized immune system (Boman et
al., 1987). However, insect immunity still lacks the high degree of specificity found in
the immune systems of vertebrates (Boman et al., 1987). An injury is often the cause of
infections, for this reason insects will often respond to an injury and other forms of
infection in a similar manner (Boman et al., 1991).
In regards to cellular immunity, different hemolymph cell types have important
roles in protecting insects. Generally, six cell types are recognized (Boman et al., 1987).
They include prohemocytes, plasmatocytes, granulocytes, coagulocytes, spherulocytes
and oenocytes. Plasmatocytes and granulocytes, which are granular cells, phagocytize
smaller bacteria and unicellular fungi (Boman et al., 1987). Many of the hemocytes work
in cooperation to encapsulate large aggregates of invading cells or parasites such as
nematodes (Boman et al., 1987). Insects respond to large numbers of invading cells by
the formation of nodules (Boman et al., 1987). In addition to being involved in
phagocytosis, plasmatocytes are also involved in capsule and nodule formation (Boman
et al., 1987).
Insects respond to an injection of live bacteria by rapidly removing them from the
hemolymph with phagocytosis and nodule formation (Boman et al., 1987). The rapid
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clearance of bacteria is followed by a short period of RNA synthesis and then subsequent
protein synthesis (Boman et al., 1991). The insect is then considered to be immunized
due to the increased circulation and activity of antibacterial agents in the hemolymph
(Boman et al., 1987). In all, approximately 15 to 20 immune proteins are synthesized in
the humoral immune response. In diapausing pupae of the saturniid Hyalophora
cecropia, also known as the giant silk moth, this increase in antibacterial activity is
mainly due to the synthesis of three novel classes of antibacterial proteins, specifically
lysozyme, attacins and cecropins (Boman et al., 1991). These immune factors were first
purified in 1980, and were first discovered in H. cecropia.
Lysozyme was the first antibacterial protein purified from insects (Boman et al.,
1987). Since its initial discovery, lysozyme has been found in many other insects
(Boman et al., 1991). Lysozyme is an enzyme, therefore it has catalytic activity. It was
found to contain 120 amino acid residues, a substrate binding groove and four disulfide
bonds (Boman et al., 1987). Lysozyme can be isolated from the larvae of nonimmunized
H. cecropia, but not in the pupae. However, lysozyme can be induced in both by the
injection of nonpathogenic bacteria (Boman et al., 1987). It is not the main antibacterial
protein responsible for immunity in insects because insects can still eliminate many
lysozyme-resistant bacteria (Boman et al., 1991). It is believed that lysozyme works in
concert with attacins and cecropins in H. cecropia, and probably in concert with the main
antibacterial proteins in other insects. Lysozyme has been shown to have limited
antibacterial activity. It is only bactericidal to a few Gram-negative bacteria such as
Bacillus megaterium, B. subtilis, and Micrococcus luteus (Boman et al., 1991).
Cecropins A and B have also been shown to kill B. megaterium and M. luteus (Boman et

20

al., 1991). B. subtilis is the only organism shown to be sensitive to lysozyme but
resistant to cecropins. The main function of lysozyme may not be bactericidal, but to
clear the murein sacculus or peptiglycan and cell wall material left after the action of
attacins and cecropins (Boman et al., 1987).
Attacins were first isolated from the immune hemolymph of H. cecropia pupae
injected with live bacteria (Boman et al., 1987). Six different attacins were isolated and
found to contain 183 to 188 amino acid residues (Boman et al., 1991). Furthermore, it
was found that attacins existed in two forms, basic and acidic peptides. It is believed that
attacins work in concert by facilitating the action of lysozyme and cecropins (Boman et
al., 1991). It was shown that attacins only act on growing bacteria, and that their
antibacterial activity is limited to a small number of bacterial species (Boman et al.,
1991). In larvae of the Chinese Oak Silk Moth, Antheraea pernyi, attacin was found to
inhibit Escherichia coli and two other bacteria in the gut (Boman et al., 1987). It was
shown that the bactericidal action of attacins is directed to the outer membrane (Boman et
al., 1991).
Of the three families of antibacterial proteins in H. cecropia, the cecropins have
the most potent bactericidal activity (Boman et al., 1987, Chen et al., 1997). The
cecropins were discovered in 1980 when Hans Boman and his research group
successfully separated them biochemically and functionally from lysozyme in H.
cecropia (Boman et al., 1991). Cecropins A and B were isolated initially (Boman et al.,
1987), since then this family has been extended to include cecropins C, D, E, and F (Chen
et al., 1997, Hultmark et al., 1982). The cecropins have highly homologous sequences
consisting of 35 to 39 amino acid residues. Cecropins in general have a broad spectrum
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of antibacterial activity against several Gram-positive and Gram-negative bacteria
(Boman, 2003). There appears to be little known about the minor cecropins C, E, and F;
cecropins A and B have been shown to be highly active against both Gram-positive and
Gram-negative bacteria, while cecropin D has shown high activity only against E. coli
and Acinetobacter calcoaceticus (Boman et al., 1991). Cecropin B is slightly more
potent than cecropin A. Furthermore, cecropins have been shown to lyse bacteria, while
leaving eukaryotic cells intact; unless they have been transformed (Boman et al., 1991,
Moore et al., 1995). Since they were originally found in H. cecropia, cecropins have
been found in other lepidopterans (butterflies and moths), dipterans (flies, etc.), other
insect orders, pigs, and a marine protochordate (Hancock et al., 1998).
It was once thought that all invertebrates including insects did not possess any
form of immunoglobulins. Hemolin was the first immunoglobulin-like molecule thought
to be part of the immune response, isolated from an invertebrate (Boman et al., 1991).
Like lysozyme, attacins, and cecropins, hemolin was first characterized from the
hemolymph of H. cecropia (Boman et al., 1991). Although little is known about
hemolin, it is the most abundant immune protein in H. cecropia. It has no antibacterial
activity, but has been shown to bind bacteria in vitro (Boman et al., 1991). Once bound,
hemolin complexes with another hemolymph protein. This complex is then bound by
hemocytes, causing it to disaggregate. Studies indicate that hemolin is involved in
self/nonself recognition (Boman et al., 1991). Hemolin is produced as part of an immune
response, but can preexist in hemolymph and the fat body (Boman et al., 1991).
Insect orders other than lepidoptera produce lysozyme, attacin-like, and cecropinlike peptides as well as unique antibacterial peptides of their own. The fly, Phormia
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terranovae, produces diptericin in response to infection (Boman et al., 1991). Honeybees
produce apidaecins and abaecin (Boman et al., 1991). The main component of bee
venom, melittin, which has some bactericidal activity, has been shown to be similar in
structure to cecropin (Boman et al., 1991).
The Cecropin Gene
The cecropin locus in H. cecropia is about 20 kb long (Boman et al., 1991). The
transcriptional region of cecropin B was the first to be sequenced from H. cecropia
(GenBank Accession No. X07404) (Boman, 2003, Xanthopoulos, et al., 1988). The
sequence was shown to include a 0.79 kb Bg/II fragment and an adjacent 0.53 kb Bg/IIPvu I fragment (Xanthopoulos et al., 1988). The gene is a typical eukaryotic gene. A
consensus sequence, known as the TATA box, is found in the promoter region of most
genes transcribed by eukaryotic RNA polymerase II. The consensus sequence is
generally 5’-TATAAAA-3’, and is important in determining the accurate position at
which transcription is initiated. The cecropin B gene contains a 5’-TATAAA-3’
sequence at position –30 in the 5’ flanking region, which is homologous to the TATA
box consensus (Fig. 1.1) (Boman, 2003, Xanthopoulos et al., 1988). Most eukaryotic
genes also have another consensus sequence in the promoter located upstream of the start
of transcription. This sequence, 5’-GG T/C AATCT-3’, is a requirement for transcription
to proceed smoothly. In the gene coding for cecropin B the CAT box is present as the
sequence 5’-CAAAT-3’ found at position –68 (Fig. 1.1) (Boman, 2003, Xanthopoulos et
al., 1988). Also a polyadenylation signal represented by the sequence 5’-AATAAA-3’ or
5’-ATTAAA-3’ is required for the transcription of eukaryotic genes. The cecropin B
gene was shown to have two such signals of the sequence 5’-AATAAA-3’, located in the
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aga tct att gga act gat ata aac acc att aat aca cat taa gat att aaa ttt tat ggt ttt gtt ccg aac aga att
aac aat tta aat tcg aat aaaaaa tat tac cgt tgt aaa ata ctc gtg att tta cga cat gtg tta ata tta aaa ttg
gaa gct ctc gtt taa aca att ttg aaa tat ttt tct gtg gtg tcc aaggag ggt tta ata aaaaag ttc caa act ctt
tga aaa agt aac tac cat aat aat gta gta gat aca tat gta gta aat att ata cgt ata aat gtg ccg ttg gac ata
att tac aat taa aaaaaa tta cgt cga ttt cat ttg aat ttt gac ccc ggt cag ctt cct ttt acg ttg cga ggg aat
tta cat tta tct acg ctg taa cat cca aac tgt tta cat ttg acc cca aat aagcgg tta tca gac ttg act ccg ctg
CAT Box
TATA Box
469 cat aag tgc taa ttt aat aaa ctc ttg caa atg tct gcg tca ttt att gta gcaaag att tta ata taa aac aga caa
5' cap
mRNA start
547 tta att tat tcg ata cat cat tca tct cgt gac ttc ttc gtg tgt ggt gtt tac cta tat atc taa att taa tat ttc
start
metasn phe ser arg ile phephephe val phe ala leu val leu ala
M N F S R I F F F V F A L V L A
625 gtt tat taa aat tta ata tat ttc gac g atg aat ttc tca agg ata ttt ttc ttc gtg ttc gct ttg gtt ctg gct

1
79
157
235
313
391

leu ser thr val ser ala ala pro glu pro lys trp lys val phe lys lys ile
L S T V S A A P E P K W K V F K K I
701 ttg tca aca gtt tcg gct gcg cca gagccg aaa tgg aaa gtc ttc aagaaa att gta agt tta ttt tat att tta ctt
779 aat agt gtt tag atc tgt att taa tga tcc att tta aaa agt aca ctt ttg aaa tta agacga cgg att ttt att tct
857 att agc cac aaa tac aat cga att tct caa tcg aaa gta ttt ttc gac atc tct gag gta gct tta gct agaaaa aat
935 att tat ttt taa aaa ata ttt ttt tgt tgc gtt tct gat tta agt atg ttt att tac aaa agt atg tat gcc aaa tta
1013 tcc tca att tat ata tca gcc aag ttt tca aaa gtc tta gaa agt aaa tat aat att att ctt taa agc tat caa cag
1091 cta tat ttg tac taa ctg ttc ttg gat att ttt tcg ttt gcaaaa tac tct att ttt taa att tgt gtt aat atc ata
1169 ttg tgg tta ctt ttt ttc ata ttc aaa ata act tca aagaaaggc taa taa tgg tta act ttt gaa acc gta cct aat
glu lys met gly arg asn ile arg asn gly ile val lys ala gly pro ala ile
E K M G R N I R N G I V K A G P A I
1247 aaa ttt gtg ttt ttt ttt cca g gaaaaa atg ggt cgc aac atc agaaac ggt att gtc aag gct ggaccg gcg atc
ala val leu gly glu ala lys ala leu gly
A V L G E A K A L G stop
1323 gcg gtt tta ggcgaa gcc aaagcg cta gga taa aat aat ttt aat tta aaa tat tat tta ttg ata aac gtt ttt gtt
polyA signal
1401 act att ata tta ttt aat tta gat aat aaa ttt aat tta taa att ttc att gtt aat aat tta att tgt cct tta ata
polyA signal
1479 ata ggt tta ata acagga cat cct tta tac ctt gcg tgc gtt tga aaa taa act tta ttt aat gt

Figure 1.1. The cecropin B gene

=exon
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=intron

3’ end of the gene (Fig. 1.1) (Boman, 2003, Xanthopoulos et al., 1988). The gene also
contains a conserved, insect specific 5’ cap site sequence, 5’-ATCATTC-3’ (Fig. 1.1)
(Boman, 2003, Xanthopoulos et al., 1988).
Cecropin B is synthesized as a prepro molecule, and there is one transcriptional
unit for preprocecropin B. The coding region contains two exons separated by only one
intron (Fig. 1.1). The transcriptional unit is 1035 bp long from the cap site to the second
polyadenylation signal. The gene contains a 90 bp-long mRNA untranslated region prior
to the start codon (AUG) (Xanthopoulos et al., 1988). The signal peptide, the
prosequence, and the first eight amino acid residues of mature cecropin B peptide are
translated from the first exon. A single 514 bp intron separates the first exon from the
second exon. The second exon contains the rest of the code for mature cecropin B plus
one glycine residue (Fig. 1.1) (Xanthopoulos et al., 1988).
Xanthopoulos et al. suggested that there may be 3 to 5 copies of the gene for
cecropin B present in the H. cecropia genome. Since cecropins A, B, and D show 62% to
65% homology, they most likely originated from gene duplications. Furthermore, it has
been shown that transcripts for cecropin A and B are made simultaneously while there is
a slight delay for the transcript of cecropin D (Boman et al., 1991). Kinetic activities of
these three cecropins have shown a similar delay in cecropin D antibacterial activity
(Boman et al., 1991).
Certain hemocytes are only slightly responsible for the synthesis of immune
proteins in H. cecropia (Boman et al., 1991). A specialized organ known as the fat body
is believed to be the main organ responsible for the synthesis of immune proteins in both
larvae and pupae of H. cecropia. In vitro studies have shown that fat bodies dissected
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from immunized H. cecropia pupae could synthesize active immune proteins (Boman et
al., 1991). It was further shown that LPS was enough to induce isolated fat bodies to
produce immune proteins (Boman et al., 1991).
Cecropin B Structure and Activity
The cecropins are strongly basic peptides containing 35 to 39 amino acid residues.
The NH2-terminal region is strongly cationic, while the COOH-terminal region is a long
hydrophobic stretch (Boman et al., 1991). All cecropins have a highly conserved
tryptophan at position 2, single and double lysines at positions 5, 8, and 9, and arginine at
position 12 (Fig. 1.2). Due to these conserved sequences found in several different
species of insects there must have been strong selection pressure for the cecropin genes
(Boman et al., 1991).
Lys(K)-Trp(W)-Lys(K)-Val(V)-Phe(F)-Lys(K)-Lys(K)-Ile(I)-Glu(E)-Lys(K)-Met(M)-Gly(G)-Arg(R)-Asn(N)-Ile(I)Arg(R)-Asn(N)-Gly(G)-Ile(I)-Val(V)-Lys(K)-Ala(A)-Gly(G)-Pro(P)-Ala(A)-Ile(I)-Ala(A)-Val(V)-Leu(L)-Gly(G)-Glu(
Ala(A)-Lys(K)-Ala(A)-Leu(L)-NH2

Figure 1.2. Primary structure of cecropin B

All cecropins are synthesized as larger prepro molecules with about 62 to 64
amino acid residues (Boman et al., 1991). In the NH2-terminus about 24 to 26 of the
amino acid residues are not present in any mature cecropin protein. About 22 of them are
probably part of the signal peptide (Boman et al., 1991). The amino acid sequence of
preproceropin B suggests that the primary translation product is processed in two, maybe
three steps to yield mature cecropin B (Van Hofsten et al., 1985). Cecropin B is
translated as a 62 amino acid residue precursor molecule including a leader peptide and a
COOH-terminal glycine residue (Fig. 1.1). The leader or signal peptide is 26 amino acid
residues long on the NH2-terminus. In vitro studies have shown that the leader peptide
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could be removed by one or more protolytic enzymes (Van Hofsten et al., 1985).
Following the activity of membrane-bound signal peptidase, a dipeptidypeptidase could
recognize the two dipeptide units in Ala-Pro-Glu-Pro (Fig. 1.1) that precede the NH2terminus of mature cecropin B (Van Hofsten et al., 1985). Natural cecropin B was found
to have an amide group bound to the COOH-terminal leucine residue (Fig. 1.2) (Van
Hofsten et al., 1985). It is likely that another step in the processing of preprocecropin B
involves the donation of nitrogen from the COOH-terminal glycine residue found in the
precursor molecule (Fig 1.1).
All the endogenous antimicrobial peptides found in plants and animals have
common structural motifs. They are typically cationic, containing excess lysine and
arginine residues, amphipathic molecules composed of 12 to 45 amino acid residues
(Hancock et al.,1998). Some are α-helical structures, especially in anionic solvents or
mixed with anionic phospholipid membranes. Others contain β-sheet secondary
structures stabilized by intramolecular cysteine disulfide bonds.
The structure of cecropin B as predicted by sequence analysis as well as circular
dichroism spectroscopy, and determined by Nuclear Magnetic Resonance (NMR) of
cecropin A is a near-perfect NH2-terminal amphipathic α-helix, and a COOH-terminal
hydrophobic α-helix joined by a flexible hinge at positions 23 and 24 (Fig. 1.2, Gly and
Pro) (Chen et al., 1997, Durell et al., 1992, Moore et al., 1995). The amphipathic α-helix
contains both a hydrophilic and a hydrophobic (lipophilic) group. The helix-bend-helix
structural motif is common among many cationic lytic peptides (Hancock et al., 1998).
The NH2-terminus of cecropin B is highly basic due to a number of lysine (n=6) and
arginine (n=2) residues. An unusually polarized NH2-terminal amphipathic helix is also a

27

very common structural motif of membrane associated proteins (Steiner et al., 1988).
Due to a lysine residue and amidation on the end, the hydrophobic COOH-terminal αhelix also has a positive charge. Cecropin B, as well as all cecropins, is devoid of
cysteine residues (Moore et al., 1996).
The lytic activity of cecropin has been widely studied. Cecropin B can cause
rapid lysis of bacterial cell membranes (Boman, 2003, Steiner et al., 1998). There are
two theories explaining the action of cecropin B. The most likely mechanism of action
involves aggregation and insertion of the peptides into the membrane, pore formation,
and then subsequent membrane disruption (Hancock et al., 1998, Wang et al., 1999). The
alternative hypothesis states that the peptides may accumulate on the membrane causing
cooperative permeabilization (Hancock et al., 1998). This destabilization of the
membrane has been dubbed the ‘carpet effect’ and is comparable to the activity of a
detergent (Wang et al., 1999). Evidence has shown that the rate of lysis is dependent on
the concentration of cecropin (Boman et al., 1991). Binding sufficient amounts of
cecropin to form a monolayer is necessary to modify the bacterial membranes (Steiner et
al., 1988). Bacteria which are resistant to cecropin still bind large amounts in a nonproductive manner. Eukaryotic cells are resistant because they avoid the binding of
cecropin B. The indication is that cecropins act stoichiometrically. The activity of
cecropin B is a matter of mass action, and is not catalytic in nature (Steiner et al., 1988).
In vitro and in vivo studies have shown that cecropins possess both antibacterial
and anticancer activity (Moore et al., 1995, Moore et al., 1996). Cecropins are thought to
induce ion channels in membranes followed by cell lysis. The rapid membrane
disruption of bacterial cells induced by cecropin B is most likely caused by primary
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membrane attack (Steiner et al., 1988). By assimilating knowledge of cecropin and other
antibacterial peptides into three dimensional atomic-scale computer models researchers
predicted that cecropins may assemble in membranes to form two types of ion channels
(Durell et al., 1992). Type I ion channels may be formed by a collection of bound dimers
with the pore formed by the transmembrane COOH-terminal helices (Durell et al., 1992).
These dimers could then be arranged into a hexagonal lattice. This could explain the
large amounts of cecropin that bind to the bacterial membrane (Steiner et al., 1988). If a
concerted conformational change of a Type I ion channel in which the pore was formed
by the NH2-terminal helices would occur, a larger Type II ion channel would be formed
(Durell et al., 1992). Cecropins as well as other antimicrobial peptides have been shown
to form ion channels on artificial membranes such as liposomes (Boman et al., 1991).
Cecropin B has been shown to lyse negative and neutral liposomes, but not positive ones
(Steiner et al., 1988, Vaara et al., 1994). It is believed that negatively charged
headgroups on the membrane surface attract and bind the positively charged NH2terminal helices (Durell et al., 1992). The hydrophobic COOH-terminal helices are then
inserted into the membrane core. The positively charged NH2-terminal helices are
pushed into the membrane by positive potential on the same side of the membrane as the
peptides (Durell et al., 1992). Transmembrane NH2-terminal helices become associated
with the hydrophilic residues faced inward forming an aqueous pore; the hydrophobic
residues then are in contact with the aliphatic phase of the membrane.
Changing the structure of the NH2-terminal α-helix of cecropin B lowers its
membrane binding affinity (Steiner et al., 1988). An antibacterial peptide containing two
amphipathic α-helical segments derived from cecropin B was shown to have a similar
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ability to lyse bacteria with a 2 to 6 fold higher potency in lysing cancer cells when
compared to cecropin A (Srisailam et al., 2000). The researchers summarized that an
amphipathic α-helix is indeed necessary for performing effective cell killing activity.
Furthermore, it was recently shown that cecropin B and cecropin B analogues which
contain at least one amphipathic α-helix lyse cells by the formation of pores (Chen et al.,
2003). In contrast, B analogues which lack an amphipathic α-helix appear to follow the
‘carpet effect’ model.
Lytic peptides, which were designed to have extra cationic residues, were less
effective in breaking liposomes and killing bacteria but more effective in lysing cancer
cells (Chen et al., 1997). It is possible that the content of the α-helix is not the main
factor of antibacterial and anticancer activity, but that the characteristics of the α-helix
itself may be important. When eukaryotic cells are transformed they usually have more
exposed anionic lipids, and microvilli on the cell membrane tend to make the surface
more accessible (Chen et al., 1997). The greater susceptibility to cationic lytic peptides
of cancer cell membranes may be a possible explanation for the difference between the
lytic activities on eukaryotic cells versus eukaryotic cancer cells.
In another study, researchers tested the effect of pH on the ability of cecropin B to
lyse liposomes of low or high levels of anionic content. They were able to show that at
high pH, cecropin B reached maximum lytic activity on both types of liposomes (Wang
et al., 1999). Here, the researchers summarized that pH is a major factor in the ability of
cecropin B to effectively lyse membranes and that secondary structure and binding ability
may not be the main determinants of lytic peptide activity.
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Although cecropins have a broad spectrum of activity against both gram-positive
and Gram-negative bacteria, the latter are generally more susceptible to cecropins
(Boman, 2003, Moore et al., 1996). The cytoplasmic membrane is the predicted site of
the lethal action of cecropin B. The cytoplasmic membrane of Gram-positive bacteria is
inherently more resistant to cecropin B (Boman, 2003, Moore et al., 1996). In Gramnegative bacteria, cecropin B must be able to cross the outer membrane to access the
cytoplasmic membrane. There is evidence to suggest that cecropin B disrupts the
bacterial outer membrane. After treatment with cecropin B, electron microscopy can be
used to show the outer membrane disruption of E. coli (Moore et al., 1996). If the
peptide initially binds through electrostatic attraction, this could explain the efficacy of
cecropin B on the outer membranes of Gram-negative bacteria. This electrostatic
attraction may be absent or reduced in the less susceptible Gram-positive bacteria.
Cecropin B initially interacts with the highly anionic outer membrane glycolipid, LPS, of
Gram-negative organisms (Hancock et al., 1998). Then the peptide accesses the
cytoplasmic membrane by local disruption of the outer membrane. Consequently, a
highly anionic outer membrane may not be completely necessary. One study showed that
cecropin B was almost as active on wild-type enteric bacteria as it was on their mutant
strains that have very defective outer membranes (Vaara et al., 1994). Furthermore,
mutant strains which had less anionic LPS were completely susceptible to cecropin B
(Vaara et al., 1994). Even though the natural L-isomer and the D-enantiomer of cecropin
B both form α-helical secondary structures (inverse conformation), they differ in their
interaction with the chiral acidic sites of LPS (Bland et al., 2001). When compared to L-
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cecropin B however, the difference in LPS interaction does not affect D-cecropin B
antibacterial activity against Gram-negative bacteria.
In summary, cecropin B is not only one of the most potent broad spectrum lytic
peptides, but it is also very effective against Gram-negative organisms. It can cause
rapid, even instantaneous lysis, of bacteria cells by disrupting the cytoplasmic membrane.
The strong cationic amphipathic α-helix is required for effective binding to the bacterial
membrane, but does not function through chiral-specific receptors. Primary membrane
attack through the formation of ion channels is the most likely cause of cell lysis.
However, the density of bound cecropin B must be high for such pores to form.
Cecropins in the Animal Kingdom
Cecropin homologues have been isolated from Antheraea pupae, the flesh-fly
Sarcophaga, the silkworm Bombyx, the tobacco hornworm Manduca, Drosophila, the
blood cells of a marine protochordate, and even porcine intestines (Boman et al., 1991,
Hancock et al., 1998, Marshall and Arenas, 2003). These findings suggest that cecropins
may be widespread throughout the animal kingdom. In every species they contribute to
the animal’s innate immunity.
Cecropin P1 was discovered when researchers isolated anti-E. coli factor from the
upper part of the porcine small intestine (Lee et al., 1989). Sequence analysis determined
this factor to be a 31 amino acid residue, cysteine-free, cecropin-like peptide. The
secondary structure is not the helix-bend-helix motif found in cecropin B, but a single
long α-helical structure (Srisailam et al., 2000). The NH2-terminus begins with an
amphipathic structure of 4 to 5 turns followed by a shorter hydrophobic region of 1 to 2
turns. Also, the carboxyl group on the COOH-terminus of natural cecropin P1 is not
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amidated (Lee et al., 1989). It has been shown that cecropin P1 kills bacteria by
instantaneous lysis, and more peptide is required to kill more bacteria (Boman et al.,
1993).
Other Antimicrobial Peptides
Cecropins were first isolated from insects, then subsequently from mammals
(Boman et al., 1987). This contradicted the belief that the use of antimicrobial peptides,
especially cecropins, was limited to the insect immune response. Soon after defensins
were first discovered in mammals, they were subsequently found in insects (Lee et al.,
1989). These findings suggested that not only cecropins, but all antimicrobial peptides
are widely distributed in the animal kingdom. This distribution is most likely due to the
fact that RNA and protein synthesis of antimicrobial peptides is much faster and easier
than facilitation of the mechanisms dependent also on cell proliferation (Lee et al., 1989).
Hence antimicrobial peptides provide fast and easy defense. In addition to diptericin
from flies and apidaecins and abaecin from honeybees, researchers have found lytic
peptides in other insects, bacteria, crustaceans, amphibians, and mammals. (Boman et al.,
1991, Hancock et al., 1998, Marshall and Arenas, 2003, Moore et al., 1996). These
peptides include defensins, magainins, bactenecins, lactoferricins, and cathelicidins as
well as tachyplesin, protegrin, indolicidin, and nisin. The innate immunity of most
animals relies heavily on the protection provided by antimicrobial peptides.
To protect their skin against microorganisms, frogs produce the antimicrobial
peptides known as magainins (Boman et al., 1991). Magainins were first isolated from
the skin of the African clawed frog, Xenopus laevis (Hancock et al., 1998). Magainins
are 23 amino acid residues long, lysine-rich, cysteine-free, and are believed to form α-
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helical secondary structures. They are synthesized in the granular gland which stores
large amounts of active peptides. Magainins are active against many Gram-positive and
Gram-negative bacteria. They have been shown to form pores in the cell membrane, but
are relatively nontoxic to untransformed eukaryotic cells (Hancock et al., 1998).
Defensins were first discovered in mammals then subsequently in insects (Lee et
al., 1989). Cecropins and defensins are very different types of molecules. Defensins are
cysteine-rich and form β-sheet secondary structures as opposed to cysteine-free α-helical
secondary structures (Hancock et al., 1998). Due to unique consensus sequences and
placement of disulfide bonds they have been divided into two families, classical and βdefensins (Selsted et al., 1996). All defensins are similar in that they have identical folds
and six cysteine residues which form three intramolecular disulfide bonds (Hancock et
al., 1998). Defensins have been shown to form ion channels on artificial membranes
(Boman et al., 1991).
β-defensins are highly cationic and contain 38 to 42 amino acid residues. They
can be found in most species including humans, birds, rats, mice, Guinea pigs, rabbits,
cattle, and sheep (Diamond et al., 2000, Huttner et al., 1998b, Selsted et al., 1996). In
mammals β-defensins are one of the two main antimicrobial peptide families (Huttner et
al., 1998b). They have been found to be expressed from both epithelial and circulating
phagocytic cells (Huttner et al., 1998a). It is believed that β-defensins help to protect the
respiratory tract and other mucosal surfaces. The first member of the β-defensin family
of mammalian antibacterial peptides discovered was Tracheal Antimicrobial Peptide
(TAP) (Diamond et al., 2000). The 38 amino acid residue-long TAP was found to be
expressed from the ciliated epithelium of the bovine trachea. Researchers found that it
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had a broad spectrum of antibacterial activity. Furthermore, in vitro studies showed that
cultured tracheal cells exposed to either bacteria or bacterial LPS could greatly increase
TAP mRNA synthesis (Diamond et al., 2000). All cattle produce at least 15 different
forms of β-defensins (Huttner et al., 1998a). Bactenecins, another antimicrobial peptide,
have also been found in bovine neutrophils (Boman et al., 1991).
In addition to β-defensins, the cathelicidins are one of the two principle
antimicrobial peptide families in mammals (Huttner et al., 1998b). Cathelicidins have
been found in humans, mice, pigs, cattle, and sheep (Hancock et al., 1998, Huttner et al.,
1998b). Neutrophil precursor (myeloid) cells of mammals contain the precursor
polypeptide (Hancock et al., 1998). The polypeptide is made up of a conserved NH2terminal precursor (cathelin) domain of about 100 amino acid residues, immediately
followed by an α-helical antimicrobial peptide of about 23 to 38 amino acid residues.
The mature peptides are only processed after the neutrophil becomes activated (Storici et
al., 1996). The secondary structure of cathelicidin-derived antimicrobial peptides is a
cationic, amphipathic, α-helical NH2-terminus and a straight hydrophobic COOHterminus (Skerlavaj et al., 1996). Circular dichroism has shown that less than 20% of the
structure is in an α-helical conformation, while 30 to 50% of the structure is in an
extended (tail) conformation (Storici et al., 1996). Unlike cecropins, cathelicidins
contain four cysteine residues which form two disulfide bonds.
More than 20 cathelicidins have been identified (Skerlavaj et al., 1996). Not only
have they been shown to have antibacterial properties, but some have been shown to bind
bacteria LPS (Hancock et al., 1998). Two bovine cathelicidins were shown to have
potent and broad spectrum antibacterial activity in vitro (Skerlavaj et al., 1996).
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However, both were cytotoxic to human erythrocytes and neutrophils at high
concentrations.
Lactoferricins are relatively new antimicrobials which are cleaved from the NH2terminus of lactoferrin, an iron-binding protein (Haukland et al., 2001). Lactoferricin B
is derived from acid-pepsin hydrolysis of bovine lactoferrin (Haukland et al., 2001, Jones
et al., 1994). The primary structure contains 25 amino acid residues, many of them
hydrophobic and cationic. Primary sequence analysis suggests that the peptide may
interact with biological membranes (Haukland et al., 2001). Lactoferricin B is believed
to disrupt the cytoplasmic membrane of bacteria. Researchers have shown that
lactoferricin B is rapidly bactericidal against a broad spectrum of bacteria (Jones et al.,
1994). However, Proteus ssp., Pseudomonas cepacia, and Serratia ssp. were resistant.
Furthermore, variables such as increased ionic strength, increased bacterial inoculum,
acid pH, the addition of 5% whole cow’s milk, and increasing concentrations of mucin all
inhibited or reduced lactoferricin B activity (Jones et al., 1994). Results indicate that this
peptide is only transiently active in vivo.
Cecropin B as a Novel Antibiotic
As previously mentioned, antibiotic resistant strains of M. haemolytica 1:A are
becoming more common (Hartman et al., 1993). Increasing patterns of antibiotic
resistance, in this and many other pathogens, are fueling a growing public concern for the
use of antibiotics in food animals. It may be beneficial to find novel antibacterial agents
that are not susceptible to existing mechanisms of resistance. The very potent broad
spectrum antibacterial activity of cecropin B makes it a likely candidate to prevent and/or
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treat infection. Since it is highly effective against Gram-negative bacteria (Vaara et al.,
1994), it may be useful for eradication of pathogens from mucosal surfaces.
One study showed that cecropins in general are 10 to 30 times (molar terms) more
potent against E. coli and Pseudomonas aerugenosa than defensins and magainins (Vaara
et al., 1994). Septic shock is primarily induced by endotoxin (LPS) secreted by Gramnegative bacteria. In an effort to determine the efficacy of antimicrobial agents at
reducing variables associated with septic shock, researchers found cecropin B to be very
effective (Giacometti et al., 2001). Researchers used mono-dose treatments of cecropins
A, B and P1 in rats infected with 2x1010 colony forming units (CFU) of E. coli. Cecropin
B was found to be the most effective at preventing bacterial growth, endotoxemia and
mortality (Giacometti et al., 2001). While some antibiotics can induce endotoxemia,
cecropin B possesses important anti-endotoxemia activity by binding LPS. This and
other studies have demonstrated the possible use of antibacterial peptides as topical or
injectible antibiotics against pathogens otherwise resistant to conventional antibiotics
(Hancock et al., 1998). The ability of cecropin B to effectively inhibit bacterial
colonization and neutralize endotoxin further exemplifies its usefulness as a novel
antibiotic. However, cost of production may limit this peptide’s practical uses. The most
cost efficient peptide synthesis methods employed at the present time are still
unreasonably expensive (Hancock et al., 1998).
One possible cost-effective approach would be to transfer the cecropin B gene
into the species of interest and let the recipient’s biosynthesis mechanisms synthesize the
peptide. Most transgenic studies involving the cecropin B gene or genes of cecropin B
homologues and analogues have been performed in plants such as tobacco, potatoes, rice
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and tomatoes. These studies have met with varying success, but suggest that cecropin B
can be expressed at the RNA and protein level, while transgenic plants display some
resistance to bacterial infection (Hancock et al., 1998). Florack et al. used several
different cecropin B gene constructs made for either expression in the cytosol or for
secretion (Florack et al., 1995). Plants transfected with a gene construct containing insect
signal peptide expressed higher levels of cecropin B mRNA than gene constructs lacking
a NH2-terminal signal peptide. The highest cecropin B mRNA expression levels were
seen in plants transfected with a gene construct containing a plant-gene-derived signal
peptide (Florack et al., 1995). Even though cecropin B mRNA could be detected, the
plants were still not resistant to bacterial wilt and bacterial wildfire. Furthermore,
researchers could not detect the cecropin B peptide. Further analysis showed that the
peptide was most likely degraded by endogenous proteases (Florack et al., 1995).
Cecropins can effectively lyse most Gram-positive and Gram-negative bacteria at very
low concentrations of 0.1 to 5 µM, but degradation due to host peptidases can be a very
limiting factor (Sharma et al., 2000). To address this problem, researchers fused the
coding sequences of mature cecropin B to the signal peptide sequence of the rice
chitinase gene which is known to direct the secretion of chitinase gene product into the
intercellular spaces of rice (Sharma et al., 2000). After transfecting rice plants with this
gene construct they were able to detect expressed cecropin B mRNA, high levels of
intercellular cecropin B peptide, and enhanced resistance to bacterial leaf blight. In yet
another study, researchers used a synthetic NH2-terminus-modified cecropin-mellitin
peptide chimera to transfect potato plants (Osusky et al., 2000). Using polymerase chain
reaction (PCR) and DNA sequencing they were able to confirm stable incorporation of
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the gene construct. Cecropin-mellitin chimera mRNA expression was confirmed by
reverse transcriptase-PCR (RT-PCR), and they were able to recover active peptide
(Osusky et al., 2000). Following highly stringent challenges these transgenic potato
plants exhibited potent bacterial resistance. It seems that researchers are well on the path
of developing bacterial resistant transgenic plants.
Very few studies are available describing transgenic mammals expressing
cecropin B or cecropin B-like peptides. In a preliminary report researchers using a
cecropin B analog to transfect mice found the mice to be resistant to Brucella abortus, a
bovine pathogen (Hagius et al., 1996). There are many indications that the transgenic
approach may be useful in enhancing bacterial resistance in food animals, thereby
reducing the use of conventional antibiotics.
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CHAPTER 2
IN VITRO SUSCEPTIBILITY OF A VIRULENT STRAIN OF MANNHEIMIA
HAEMOLYTICA 1:A TO CECROPIN B

Introduction
Mannheimia haemolytica 1:A is a gram-negative bacterium generally regarded as the
cause of bovine pneumonic pasteurellosis. While M. haemolytica 1:A can be a normal resident
of the bovine nasal passage, under times of stress, the bacterium proliferates in the upper
respiratory tract (URT). The use of antibiotics to treat pneumonic pasteurellosis has been
generally successful (Frank, 1986). However, M. haemolytica 1:A is developing an increasing
pattern of resistance to drugs commonly used to treat the disease (Hartman and Geryl, 1993).
Due to an increasing pattern of antibiotic resistance among many species of bacteria, public
concern for the use of antibiotics in food animals is once again on the rise (Ferber, 2003). With
the occurrence of antibiotic resistant strains of bacteria, the appropriate use of antibiotics should
include exposing M. haemolytica 1:A to sufficient concentrations of the antimicrobial agents for
an appropriate duration as to minimize the development of resistant strains (Watts et al., 1994).
Cecropins are small, strongly basic proteins, which have a broad spectrum of
bactericidal activity (Steiner et al., 1988) but are unable to disrupt eukaryotic cells (Boman et al.,
1991). This clearly implicates their possible usefulness as novel antibiotics. Cecropins have
been shown to have direct action on bacterial membranes (Steiner et al., 1988), although the
exact mechanisms are not yet fully understood. Primary membrane attack is believed to be the
cause of both Gram-positive and Gram-negative bacteria lysis (Steiner et al., 1988).
Furthermore, binding sufficient amounts of cecropin to form a monolayer is necessary to modify
the bacterial membranes. Although cecropin B has a broad spectrum of activity against both
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Gram-positive and Gram-negative bacteria, the latter are generally more susceptible (Moore et
al., 1996). Cecropin B initially interacts with the highly anionic outer membrane glycolipid,
LPS, of Gram-negative organisms (Hancock et al., 1998). The peptide then accesses the
cytoplasmic membrane by local disruption of the outer membrane.
Cecropin B was chosen for its availability and efficacy. Studies have demonstrated the
possible use of cecropin B as topical or injectable antibiotics against pathogens otherwise
resistant to conventional antibiotics (Hancock et al., 1998). It has been shown to possess the
broadest bactericidal activity of the cecropin family (Chen et al., 1997). The purpose of this
study was to determine, in vitro, the antibacterial efficacy of cecropin B for a virulent strain of
M. haemolytica 1:A. Also, an attempt was made to determine the stability of cecropin B activity
in the bovine nasal mucosa.
Materials and Methods
Preparation of Virulent M. haemolytica 1:A Inoculum
A preparation of a virulent M. haemolytica 1:A strain, lyophilized in skim milk, was
reconstituted with 1 ml of sterile distilled H2O. The suspension was streaked for isolation on
yeast blood agar plates with 10% horse serum (10% YBP) and allowed to incubate for 18-24
hours at 37oC in a candle jar (5% CO2 atmosphere). Bacterial growth was visually identified as
M. haemolytica 1:A. Isolated colonies were added to 10 ml of sterile Brain Heart Infusion (BHI)
broth (Becton Dickinson and Co., BD Microbiology Systems, Sparks, MD) and incubated for an
additional 18-24 hours at 37oC. A 100 µl aliquot of this culture was added to 10 ml of sterile
BHI broth and incubated for another 8 hours at 37oC. The concentration was adjusted to
approximately 8 x 106 colony-forming units (CFU) with sterile BHI broth.
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Minimum Inhibitory Concentration (MIC)
MICs were determined according to the procedures outlined by the National Committee
for Clinical Laboratory Standards (NCCLS). The broth microdilution method was performed in
96-well plates. BHI broth was used instead of the recommended Mueller-Hinton broth
(NCCLS). Although Mueller-Hinton broth is acceptable for the growth of M. haemolytica 1:A,
BHI broth was chosen to meet specific growth requirements and provide consistent growth. Test
wells containing two-fold dilutions of cecropin B were incubated in triplicate. Each test well
was inoculated with a final concentration of 5 x 104 CFU of M. haemolytica 1:A per well. Each
plate included positive control (no cecropin B, in triplicate) and negative control (no M.
haemolytica 1:A) wells. Due to the expense of Cecropin B (Sigma, Sigma-Aldrich Corporation,
St. Louis, MO), tetracycline was used first, to standardize the assay. Results were read both
visually and with a Dynatech plate reader (Dynatech Laboratories Inc., Chantily, VA) at 16, 20
and 24 hours of incubation. The MIC was determined as the lowest concentration of the
antimicrobial agent, which completely inhibited visible growth.
Statistical Analysis
Data were analyzed by use of two-factor ANOVA.
The Stability of Cecropin B in the Bovine Nasal Mucosa
To determine the stability of cecropin B in the bovine nasal mucosa, nasal secretions
were collected using a modified 1 ml pipette bent at a 45o angle approximately 4 to 5 cm from
the end and attached to 3 mm diameter tubing that was connected to a 10 ml evacuated tube by a
16 gauge needle. A vacuum was created in the tube using an electric vacuum pump (General
Electric Model 5KH35GN106CX, Benton Harbor, MI). The pipette was inserted into each
nostril to aspirate nasal secretions. Five milliliters of sterile Dulbecco’s phosphate buffered
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saline (duPBS) (pH7.2) was then aspirated through the pipette and collected along with mucus in
the tube. Nasal secretions were pooled from three calves.
For the assay, 200 µl of M. haemolytica 1:A culture (mid-log-phase, final concentration
of 105 CFU/ml) were mixed with 200 µl of cecropin B diluted in sterile PBS (pH 7.2) (8 µg/ml),
as well as 200 µl of cecropin B diluted in pooled bovine nasal secretions (8 µg/ml). The final
concentration of cecropin B in each culture was 4 µg/ml. The two assay cultures were allowed
to incubate at 37oC. At time intervals 0, 20, and 60 minutes, the assay cultures were diluted 10-1
to 10-6, and plated on 10% YBP. The plates were allowed to incubate at 37oC and colonies were
counted at 24 hours. The time intervals of 0, 20, and 60 minutes were arbitrarily chosen.
Results
When visually observed, the MIC of tetracycline was 32 µg/ml as seen in Table 2.1. At
16 hours M. haemolytica 1:A growth, as determined by optical density at 630 nm, in the positive
control wells was significantly higher (P<0.05) than growth in all wells containing tetracycline
(Figure 2.1). At 20 and 24 hours M. haemolytica 1:A growth in the positive control wells was
significantly higher (P<0.05) than growth at all concentrations of tetracycline except the lowest
concentration of 2 µg/ml. Growth measured in these wells was equal to the growth measured in
the positive control wells. Growth measured for inhibiting concentrations 128, 64, and 32 µg/ml
was not significantly different between 16, 20, or 24 hours of incubation. Wells containing these
inhibiting concentrations did not show a significant increase or decrease from 16 to 24 hours. At
16 hours of incubation in the wells where growth was not inhibited, concentrations 16, 8, 4, and
2 µg/ml, growth significantly increased (P<0.05) as the concentration of tetracycline decreased.
At 20 and 24 hours growth slightly decreased as the concentration of tetracycline decreased from
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16 to 4 µg/ml and then increased significantly (P<0.05) as the concentration of tetracycline
decreased from 4 to 2 µg/ml.
Table 2.1. Tetracycline susceptibility as determined by visual growth of M. haemolytica 1:A.

Mean O.D. @630nm

Tetracycline
Visual
Concentration
Growth
16hr 20 hr
24hr
(µg/ml)
128
64
32
16
+
+
+
8
+
+
+
4
+
+
+
2
+
+
+
(+) control
+
+
+

1.00
0.80
0.60
0.40
0.20

F

C
C D B A
D E

G G G

C
C D A A
C D E

G G G

C D
D EE B
B
E FF
G G G

0.00

16 hr

20 hr

24 hr

Time
128 µg/ml

64 µg/ml

32 µg/ml

16 µg/ml

8 µg/ml

4 µg/ml

2 µg/ml

(+) control

Figure 2.1. Tetracycline susceptibility of M. haemolytica 1:A as determined by optical density
measured at 630 nm. Optical densities sharing the same letter are not statistically different
(P>0.05).
When visually observed, the MIC of cecropin B was 2 µg/ml as seen in Table 2.2. At 16,
20, and 24 hours, M. haemolytica 1:A growth, as determined by optical density at 630 nm, in the
positive control wells and wells containing 1 µg/ml were significantly higher (P<0.05) than
growth in the wells containing 128, 64, 32, 16, 8, 4, and 2 µg/ml of cecropin B (Figure 2.2).
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Table 2.2. Cecropin B susceptibility as determined by visual growth of M. haemolytica 1:A.

Mean O.D. @630nm

Cecropin B
Visual
Concentration
Growth
16hr
20 hr
24hr
(µg/ml)
128
64
32
16
8
4
2
1
+
+
+
(+) control
+
+
+

1.20
1.00
0.80
0.60
0.40
0.20
0.00

A
B

B B

B

C

D D D D D D D

D D D D D D D

16 hr

D D D D D D D

20 hr

24 hr

Time
128 µg/ml
2 µg/ml

64 µg/ml
1 µg/ml

32 µg/ml
(+) control

16 µg/ml

8 µg/ml

4 µg/ml

Figure 2.2. Cecropin B susceptibility of M. haemolytica 1:A as determined by optical density
measured at 630 nm. Optical densities sharing the same letter are not statistically different
(P>0.05).
Growth measured for concentrations, 128, 64, 32, 16, 8, 4, and 2 µg/ml, was not significantly
different from 16 to 24 hours. Wells containing these inhibiting concentrations of cecropin B did
not show a significant increase or decrease from 16 to 24 hours. Growth in wells containing 1
µg/ml significantly increased between the 16 and 20 hour readings and again between the 20 and
24 hour readings. At 16 hours of incubation, growth measured in wells containing 1 µg/ml was
significantly lower (P<0.05) than growth measured in the positive control wells. By 20 hours of
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incubation there was no significant difference (P<0.05) between these wells. At 24 hours of
incubation growth in the wells containing 1 µg/ml of cecropin B was significantly higher than
that of the positive control wells. Growth measured in the positive control wells did not increase
or decrease from 16 to 24 hours of incubation.
When diluted in PBS (pH 7.2), a 4 µg concentration of cecropin B completely inhibited
approximately 105 CFU of M. haemolytica 1:A within 20 minutes (Figure 2.3). No change was
observed at 60 minutes of incubation. When diluted in pooled bovine nasal secretions, a 4 µg
concentration of cecropin B again completely inhibited approximately 105 CFU of M.
haemolytica 1:A within 20 minutes (Figure 2.4). Again no change was observed at 60 minutes
of incubation.
Discussion
To provide protection against pneumonic pasteurellosis, M. haemolytica 1:A should not
be allowed to colonize the upper respiratory tract. The use of an effective antibiotic to inhibit the
rapid colonization of M. haemolytica 1:A in the nasopharynx should reduce the occurrence of
pneumonic pasteurellosis in cattle arriving at the feedlots. There have been very few studies
aimed at the use of antibiotics to eliminate colonization of the nasal passage. However, in one
such study the use of oxytetracycline or feeding chlortetracycline at the feedlots did not reduce
or eliminate the colonization of M. haemolytica 1:A in the nasopharynx (Frank et al., 2000b). In
calves experimentally infected with M. haemolytica 1:A, tilmicosin was effective in alleviating
clinical signs and pathology findings of pneumonic pasteurellosis as well as the presence of
viable organisms in the lung (Morck et al., 1997). Furthermore, the lung could be protected for
up to 72 hours with concentrations well above the MIC for M. haemolytica 1:A (Morck et al.,
1997). Researchers have also shown that a single dose of tilmicosin was more effective
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Figure 2.3. Antibacterial activity of cecropin B against M. haemolytica 1:A. Mid-log-phase M.
haemolytica 1:A cells (105 CFU/ml) were incubated with cecropin B (4 µg/ml) for 60 minutes at
37°C.
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Figure 2.4. Antibacterial activity of cecropin B against M. haemolytica 1:A in the presence of
pooled bovine nasal secretions. Mid-log-phase M. haemolytica 1:A cells (105 CFU/ml) were
incubated with cecropin B (4 µg/ml) for 60 minutes at 37°C.
at reducing mortality due to pneumonic pasteurellosis than ceftiofur, oxytetracycline, or
trimethoprim-sulfadoxine (Shyrock et al., 1996). In other studies focused on decreasing M.
haemolytica 1:A colonization in the nasopharynx, both tilmicosin and florfenicol were shown to
be effective (Frank et al., 2000a, Frank et al., 2002). Both antibiotics inhibited M. haemolytica
1:A colonization in the nasal passage for up to several days (Frank et al., 2002).
In this study the MIC of tetracycline was determined as a quality control. The MIC was
measured to be 32 µg/ml. This value is consistent with that obtained in a recent study which
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showed the MIC of tetracycline for 90% of the M. haemolytica 1:A isolates tested to be 32 µg/ml
(Watts et al., 1994).
Results of the present study indicate that cecropin B is very effective in inhibiting this
virulent strain of M. haemolytica 1:A. Growth of this isolate was inhibited at the MIC of 2
µg/ml. However, only one isolate was tested. These results may warrant further testing with
larger numbers of isolates to more accurately determine susceptibility breakpoints for M.
haemolytica 1:A.
The very potent broad spectrum antibacterial activity of cecropin B makes it a likely
candidate to prevent and/or treat infection. Since it is highly effective against Gram-negative
bacteria (Vaara et al., 1994), it may be useful for eradication of pathogens from mucosal
surfaces. One problem to this approach is that the peptide may be degraded by endogenous
proteases (Florack et al., 1995, Sharma et al., 2000). While cecropin B can effectively lyse
bacteria at very low concentrations, degradation can be a limiting factor. Although proteolytic
enzymes in the bovine nasal mucosa may degrade the peptide and inhibit antibacterial activity,
no inhibition was observed by incubating cecropin B in bovine nasal secretion. Furthermore,
cecropin B was able to completely inhibit M. haemolytica 1:A growth within 20 minutes of
incubation. The ability of cecropin B to effectively inhibit bacterial colonization as well as
neutralize endotoxin further exemplifies its usefulness as a novel antibiotic. However, cost of
production may be yet another factor that will limit this peptide’s practical uses. The most cost
efficient peptide synthesis methods employed at the present time are still unreasonably expensive
(Hancock et al., 1998). Therefore, the use of cecropin B as a topical or injectable antibiotic may
not be a suitable approach.
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CHAPTER 3
TRANSGENIC EXPRESSION OF CECROPIN B IN THE NASAL PASSAGE OF
CATTLE CHALLENGED WITH A VIRULENT STRAIN OF MANNHEIMIA
HAEMOLYTICA 1:A

Introduction
The major etiologic agent of bovine pneumonic pasteurellosis is Mannheimia
haemolytica 1:A (Dalgleish, 1990, Frank, 1986). Vaccines which provide cattle with
effective and consistent immunity to pneumonic pasteurellosis are not yet available.
Most veterinarians rely on antimicrobial agents to treat this disease. However, studies
have shown M. haemolytica 1:A to have an increasing pattern of resistance to many of
the commonly used antibiotics (Hartman et al., 1993).
The diapausing pupae of the saturniid Hyalophora cecropia, also known as the
giant silk moth, respond to bacterial infection with the synthesis of highly effective
antibacterial peptides (Boman et al., 1991). Although the moth synthesizes three
different classes of antibacterial peptides, the cecropins have the most effective
bactericidal activity (Boman et al., 1987, Chen et al., 1997). Cecropin B has a broad
spectrum lytic activity, and is very effective against Gram-negative organisms (Vaara et
al., 1994).
The very potent antibacterial activity of cecropin B makes it a likely candidate to
prevent and/or treat infection. Since it is highly effective against Gram-negative bacteria,
it may be useful for eradication of pathogens from mucosal surfaces. Few studies are
available describing transfected mammals expressing cecropin B or cecropin B-like
peptides; however there are many indications that a transgenic or gene therapeutic
approach may be useful in enhancing bacterial resistance in cattle.
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Materials and Methods
Transposon-based Plasmid Vector
A transposon-based plasmid vector containing the cecropin B gene was obtained
from Dr. Richard Cooper (Cooper, 1998, Cooper and Enright, 1996). This plasmid
contains the cecropin B gene linked to an acute phase response promoter (APR) was
inserted between 2 transposon insertion sequences. The plasmid also contained the Ptac
promoter for the transcription of transposase (Ats). Ats was also encoded on the plasmid.
The plasmid was delivered by aerosol while complexed to a transfection reagent
(Superfect®, Qiagen, Inc., Valencia, CA). Superfect® is designed to deliver DNA to the
nucleus of eukaryotic cells. It is a specifically designed activated dendrimer. The reagent
complexes with DNA and arranges it in compact structures to ease entry into the cell.
Superfect® complexed with the plasmid possesses a net positive charge, which allows it
to bind negatively charged cell surface receptors. The reagent also stabilizes plasmid
DNA inside the cell by pH inhibition of lysosomal nucleases. The plasmid was
complexed with Superfect® at a 1:3 ratio.
The aerosol was administered using methods derived from a previous study
(Brennan et al., 1998). The delivery system for the aerosol was a modified siphon-feed
gun (Sears Craftsman Model 491.167060, Hoffman Estates, IL.) with a 7 cm piece of
tubing attached to the nozzle. The gun was attached to a nitrogen tank and 20 kg of
pressure was used to intranasally aerosolize the suspension. All personnel involved in the
DNA delivery were wearing disposable coveralls, disposable latex gloves and HEPA
filtered respirators to prevent accidental exposure. The disposable coveralls and latex
gloves were properly disposed as biohazardous waste.
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Experiment I
Seven (n=7) 300-500 lbs. crossbred beef calves were brought to the Louisiana
State University Veterinary Science Farm in Baton Rouge, LA and kept on pasture.
Calves were randomly assigned to one of 2 groups. One group was designated the
treatment group (n=4), and the other was designated the control group (n=3). The two
groups were not isolated during the experiment. Nasal swabs were collected from all
calves prior to transfection. Each of the 4 treated calves were given 50 µg of DNA
complexed with a transfection reagent (Superfect®, Qiagen, Inc., Valencia, CA)
suspended in 3 ml of sterile phosphate buffered saline (PBS) (pH 7.2) per nostril.
Control calves were given only the transfection reagent suspended in 3 ml of sterile PBS
(pH 7.2) per nostril. Control calves were aerosolized first then allowed to return to the
pasture. Next the treated calves were aerosolized and allowed to return to pasture. Nasal
swabs were collected on 0, 3, 7, 14, and 21 days post transfection and submitted for DNA
polymerase chain reaction (PCR).
Experiment II
Eight (n=8) 300-500 lbs. crossbred beef calves were brought to the Louisiana
State University Veterinary Science Farm in Baton Rouge, LA and kept on pasture.
Calves were randomly assigned to one of 2 groups. One group was designated the
treatment group (n=4), and the other was designated the control group (n=4). The two
groups were isolated throughout the experiment. Nasal swabs, nasal aspirates and blood
were collected from all calves prior to transfection. Each of the 4 treated calves were
given 25 µg of DNA complexed with a transfection reagent (Superfect®, Qiagen, Inc.,
Valencia, CA) suspended in 3 ml of sterile PBS (pH 7.2) per nostril. Control calves were
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given only the transfection reagent suspended in 3 ml of sterile PBS (pH 7.2) per nostril.
Control calves were aerosolized first then allowed to return to the pasture. The treated
calves were aerosolized one at a time, with that calf being the only calf allowed in the
chute at the time. Control calves were isolated from this event. All 8 (treated and
control) calves were then inoculated intranasally with 2 x 107 to 2 x 108 colony forming
units (CFU) of a virulent strain of M. haemolytica 1:A suspended in 3 ml of sterile
Dulbecco’s PBS (duPBS) (pH 7.2) (Sigma Chemical Co., St. Louis, MO) per nostril.
Following the inoculation, groups were trucked separately 100 miles for 3 hours to stress
them. Serum, nasal aspirates, and nasal swabs were collected on 0, 3, 7, 14, 21, and 28
days post transfection/challenge. Samples were analyzed by bacterial culture, real-time
PCR, real-time reverse transcriptase (RT) PCR, and ELISA. All samples on day 0 were
collected prior to any calf receiving the DNA aerosol. All calves were examined daily
for clinical signs of respiratory disease to eliminate the possibility of an adventitious
infection.
Experiment III
Twelve (n=12) 300-500 lbs. crossbred beef calves were brought to the Louisiana
State University Veterinary Science Farm in Baton Rouge, LA and kept on pasture.
Calves were randomly assigned to one of 3 groups. Two groups were designated the
treatment groups (n=4 each), and the other was designated the control group (n=4). The
three groups were again isolated throughout the experiment. Nasal swabs, nasal
aspirates, and blood were collected from all calves prior to transfection. Each of the 4
treated calves in one group were given 50 µg of DNA complexed with a transfection
reagent (Superfect®, Qiagen, Inc., Valencia, CA) suspended in 3 ml of sterile PBS pH 7.2
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per nostril, as previously described. Each of the 4 treated calves in the other treatment
group were given 100 µg of DNA complexed with a transfection reagent (Superfect®,
Qiagen, Inc., Valencia, CA) suspended in 3 ml of sterile PBS (pH 7.2) per nostril.
Control calves were given only the transfection reagent suspended in 3 ml of sterile PBS
(pH 7.2) per nostril. Control calves were aerosolized first then allowed to return to the
pasture. The treated calves were aerosolized one at a time, with that calf being the only
calf allowed in the chute at the time. The two treated groups were aerosolized on
different days. Control calves were isolated from this event. All 12 (treated and control)
calves were inoculated intranasally with 2 x 107 to 2 x 108 CFU of a virulent strain of M.
haemolytica 1:A suspended in 3 ml of sterile duPBS (pH 7.2) (Sigma Chemical Co., St.
Louis, MO) per nostril. Following the inoculation, groups were trucked separately 100
miles for 3 hours to stress them. Serum, nasal aspirates and nasal swabs were collected
on 0, 3, 7, 14, 21, and 28 days post transfection/challenge. Samples were analyzed by
bacterial culture, real-time PCR, real-time RT-PCR, and ELISA. All samples on day 0
were collected prior to any calf receiving the DNA aerosol. All calves were examined
daily for clinical signs of respiratory disease to eliminate the possibility of an
adventitious infection.
Preparation of a Virulent M. haemolytica 1:A Strain
A preparation of a virulent M. haemolytica 1:A strain, lyophilized in skim milk,
was reconstituted with 1 ml of sterile distilled H2O. The suspension was streaked for
isolation on yeast blood agar plates with 10% horse serum (10% YBP) and allowed to
incubate for 18-24 hours at 37oC in a candle jar (5% CO2 atmosphere). Bacterial growth
was visually identified as M. haemolytica 1:A. Isolated colonies were picked and added
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to 1 ml of sterile duPBS (pH 7.2) until the solution became turbid. The solution was then
used to streak sixteen 10% YBP confluently which were incubated for an additional 1824 hours at 37oC. Bacterial growth was harvested using a sterile cotton swab and
suspended in 20 ml of sterile duPBS (pH 7.2). The concentration was adjusted to
approximately 2 x 107 to 2 x 108 CFU with sterile duPBS (pH 7.2).
Nasal Aspirate Collection
Nasal aspirates were collected using a modified 1 ml pipette bent at a 45o angle
approximately 4 to 5 cm from the end and attached to 3 mm diameter tubing that, in turn,
was connected to a 10 ml evacuated tube by a 16 gauge needle. A vacuum was created in
the tube with a vacuum pump (General Electric Model 5KH35GN106CX, Benton
Harbor, MI). The pipette was inserted into each nostril to aspirate nasal secretions. Five
milliliters of sterile duPBS (pH 7.2) were then aspirated through the pipette and collected
along with mucus into the tube.
Serum Sample Collection
Blood samples were collected into plain evacuated tubes, and allowed to clot at
room temperature (approx. 20o C) for 2 hours. Then they were centrifuged at 850 x g for
20 minutes (Beckman TJ-6 Centrifuge, Palo Alto, CA).
PCR Amplification
Total DNA was purified from nasal swabs collected on days 0, 3, 7, 14 and 21 of
experiment I using Qiagen DNeasy® extraction kits (Qiagen, Inc., Valencia, CA).
Forward and reverse primers were designed to target the cecropin B gene. The forward
primer Vec1 (5’-CTACGCTGTAACATCCAAACT-3’) and reverse primer Vec2 (5’-
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CGCTTTGGCTTCGCCTAAAA-3’) were selected. These primers amplify a 946-bp
region of the cecropin B gene (bases 401 to 1346, GenBank accession no. X07404). The
reaction mixture contained a 50 µM concentration of the forward primer and a 50 µM
concentration of the reverse primer. PCR’s were performed using PTC-100
Programmable Thermal Controller (MJ Research, Inc., Watertown, MA). The thermal
cycler program used was 96ºC for 5 minutes, then 35 cycles at 96ºC for 30 seconds, 58ºC
for 30 seconds, and 72ºC for 30 seconds, followed by 72ºC for 5 minutes. All PCR
products were electrophoresed on a 1% agarose gel in Tris-acetate-EDTA (TAE) buffer,
and the DNA was visualized by ethidium bromide staining under UV fluorescence.
Quantitative Real-time PCR and RT-PCR
Forward and reverse primers as well as a fluorescent probe were designed to
target the cecropin B gene. The forward primer CB1-5’ (5’TGGGTCGCAACATCAGAAAC-3’), reverse primer CB1-3’ (5’CCTAGCGCTTTGGCTTCG-3’), and fluorescent CB gene probe (5’-FAMTCGCCGGTCCAGCCTTGACAATA-TAMRA-3’) were selected. These primers
amplify a 76-bp region inside the transcribed region of the cecropin B gene (bases 1276
to 1334, GenBank accession no. X07404). The reaction mixture contained a 20 µM
concentration of the forward primer, a 20 µM concentration of the reverse primer, and a 7
µM concentration of the fluorescent probe. Real-time PCR, RT-PCR, and probe
detection were performed using an ABI PRISM 7900 Sequence detection system (PE
Applied Biosystems, Perkin-Elmer, Foster City, CA). The standard real-time PCR
thermal cycler program used was 50ºC for 2 minutes, 95ºC for 10 minutes, 40 cycles at
95ºC for 15 seconds, and 60ºC for 1 minute. The standard real-time RT-PCR thermal
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cycler program used an additional step of 48ºC for 30 minutes to convert RNA into
cDNA.
Total DNA was purified from nasal swabs collected on days 0, 3, 7, 14, 21 and 28
of experiments II & III using Qiagen DNeasy® extraction kits (Qiagen Inc., Valencia,
CA). The quantitative results were based on a 5-fold dilution of plasmid DNA. Each
total genomic DNA extraction was normalized by using an endogenous control (the
eukaryotic 18s rRNA gene) as an active reference to adjust for differences in the amount
of total DNA added to each reaction mixture. For an individual calf the relative level of
cecropin B DNA in each sample (days 3, 7, 14, 21, and 28) was determined as a ratio
compared to day 0 (the calibrator). Results were expressed as arbitrary units (AU).
Total RNA was purified from nasal aspirates collected on days 0, 3, 7, 14, 21, and
28 of experiments II & III using Qiagen RNeasy® extraction kits (Qiagen Inc., Valencia,
CA). The quantitative results were based on a 5-fold dilution of bovine RNA containing
cecropin B mRNA. Each total genomic RNA extraction was normalized by using an
endogenous control (the eukaryotic 18s rRNA gene) as an active reference. In order to
adjust for differences in the amount of total RNA added to each reaction mixture. For an
individual calf the relative level of cecropin B mRNA in each sample (days 3, 7, 14, 21,
and 28) was determined as a ratio compared to day 0 (the calibrator). Results were
expressed as arbitrary units (AU).
Bacterial Culture
Nasal aspirates collected from 0, 3, 7, 14, 21, and 28 days post
transfection/challenge were analyzed by bacterial culture. Aliquots of these samples
were diluted in sterile duPBS (pH 7.2) to 1:10, 1:100, and 1:1000 of the original

56

concentration. Within one to four hours after collection, small amounts (0.1 ml) of each
dilution and of the undiluted sample were directly streaked onto separate 1% YBP (Difco,
Becton, Dickinson and Co., Sparks, MD.). The plates were allowed to incubate in a 5%
CO2 atmosphere for up to 72 hours at 37oC. The plates were observed for bacterial
growth every 24 hours. Isolated colonies of M. haemolytica 1:A as well as the calves’
bacterial flora were counted, identified, and recorded.
Small amounts (0.1 ml) of the undiluted sample were inoculated into Difco
thioglycollate enrichment medium (Becton, Dickinson and Co., Sparks, MD.) plus 0.1%
horse serum. The thioglycollate tubes were allowed to incubate for up to 72 hours at
37oC. The tubes were observed for bacterial growth every 24 hours. Observed growth
was then recorded and streaked onto 1% YBP, which were incubated in a 5% CO2
atmosphere for 24 hours at 37oC.
Suspected M. haemolytica 1:A colonies were first identified on the basis of
colonial morphology. These representative colonies were then streaked onto manitol salt
and McConkey agar plates as well as triple sugar iron (TSI), citrate, and urea slants
(Difco, Becton, Dickinson and Co., Sparks, MD.). Smears of these representative
colonies were also Gram (Difco, Becton, Dickinson and Co., Sparks, MD.) stained. M.
haemolytica 1:A colonies were identified on the basis of morphology, cultural, and
biochemical characteristics of the isolates in pure culture as well as by the presence of
hemolysis, agglutination, and oxidase (Difco, Becton, Dickinson and Co., Sparks, MD.)
test. All findings were recorded.
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Detection of Cecropin B by ELISA
To test for cecropin B in nasal aspirates collected from days 0, 3, 7, 14, 21, and 28
post transfection/challenge of experiment III, flat bottom wells of Immunolon 1 96-well
microtitration plates (Dynatech Laboratories, Chantilly, VA) were coated with 100 µl of
a 1:2 dilution of each nasal aspirate in 0.05 M sodium carbonate buffer (.03 M NaHCO3
and .02 M NaCO3, pH 9.6) and incubated overnight at 4oC for fixation. Serial dilutions
of a positive control nasal aspirate spiked with 2 µg/ml of cecropin B were included on
each plate. The positive controls were serially diluted 1:2 to 1:256 (2 µg/ml to 0.015625
µg/ml). Also included on each plate were several negative control nasal aspirates which
were diluted 1:2. Plates were washed 3 times with PBS (pH 7.2) containing 0.05% (v/v)
Tween 20 (PBST). Rabbit anti-cecropin B serum (obtained from Dr. William Todd, LSU
Dept. of Vet. Science, Baton Rouge, LA.) diluted 1:200 in PBST was added to each well
and incubated 1.5 hours at room temperature. After washing 3 times with PBST, the
plates were incubated 1.5 hours with 100 µl of alkaline phosphate-conjugated anti-rabbit
IgG (Kirkegaard and Perry, Gaithersberg, MD) diluted 1:1000 in PBST. The plates were
washed 3 times with PBST and color was developed by adding 100 µl of substrate buffer
containing 1 mg/ml p-nitrophenyl phosphatase, 10% diethanolamine, and 5 mM MgCl2
(pNPP) (pH 9.8) (Kirkegaard and Perry, Gaithersberg, MD). The absorbance was read at
405 nm in a microplate reader (Benchmark Plus microplate spectrophotometer, Bio-Rad
Life Science, Hercules, CA).
The amounts of cecropin B in nasal aspirates were determined using regression
equations. Using the serially diluted positive controls, log O.D. values were plotted
against the log dilution, generating a regression equation for each plate. Sample
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concentrations were calculated by substituting its log O.D. value into the equation.
Subtracting the mean concentration of the negative controls plus 2 times the standard
deviation from the sample concentration resulted in a corrected cecropin B concentration.
Only corrected cecropin B concentrations were reported.
Detection of Antibodies Against M. haemolytica 1:A by ELISA
A whole cell M. haemolytica 1:A antigen preparation was obtained using
previously described methods (Brennan et al., 1998). The whole cell M. haemolytica 1:A
antigen was diluted 1:200, in 0.1 M sodium carbonate buffer (.06 M NaHCO3 and .04 M
NaCO3). The flat bottom wells of Immunolon 1 96-well microtitration plates were then
coated with 100 µl of the antigen dilution. The plates were wrapped in cellophane and
incubated overnight at 4oC for fixation. After 24 hours of incubation, the plates were
washed three times with dH2O + NaCl + Tween 20, then blocked with 100 µl NET buffer
(0.1M NaCl, 1mM EDTA, and 10mM Tris, pH 8.0) plus 10% heat inactivated goat serum
per well for 30 minutes at 37oC. The plates were washed as before and 100 µl of each
serum sample, diluted 1:200 in NET + 10% goat serum, was added to the appropriate
wells. Serial dilutions of a positive control serum sample pooled from high titer calves
were included on each plate. The positive controls were serially diluted 1:200 to
1:25,600. Also included on each plate were several negative control serum samples
which were diluted 1:200. Plates were then incubated for 1 hour at 37oC and washed as
before. Antigen-antibody complexes were detected by adding 100 µl of horseradish
peroxidase conjugated affinity purified goat anti bovine immunoglobulins IgG heavy &
light chain, IgG1 heavy chain, IgG2 heavy chain, IgA-α chain, or IgM-µ chain
(Kirkegaard and Perry, Gaithersberg, MD) diluted 1:750 in NET + 10% goat serum per
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well. Plates were again incubated for 1 hour at 37oC and then washed. 100 µl of substrate
2-2’azino-di-3-ethylbenzothiazolin sulfone-6 (ABTS) (Kirkegaard and Perry,
Gaithersberg, MD) was added to each well and allowed to react at room temperature for
ten minutes. The reaction was stopped by the addition of 10% sodium dodecyl sulfate
(SDS) (100 µl) per well. Optical densities were read immediately with an ELISA plate
reader at a wavelength of 405 nm.
Antibody responses in nasal aspirates were also measured by ELISA similarly to
serum samples with a few exceptions. Microtitration plates were coated with antigen
overnight as previously described. Nasal aspirates were diluted 1:2 in NET + 10% goat
serum. Positive controls were serially diluted 1:2 to 1:256, and negative controls were
diluted 1:2.
Antibody titers for serum and nasal aspirates were determined using regression
equations. Using the serially diluted positive controls, log OD values were plotted
against the log dilution, generating a regression equation for each plate. Sample titers
were calculated by substituting its log OD value into the equation. Subtraction of the
mean titers of the negative control plus 2 times the standard deviation from the sample
titer resulted in a corrected titer. Only corrected titers were reported.
Statistical Analysis
Data were log transferred (natural log) to stabilize variance terms. The SAS
statistical package GLM procedure (SAS Institute Inc.) was used to analyze the data
through a repeated measures analysis of variance (ANOVA) analyzed as a split-plot
arrangement of treatments with ‘group’ and ‘calves within group’ as main plot effects
and ‘day’ and ‘group by day’ as subplot effects. All comparisons were considered
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significant at P<0.05. Where overall tests indicated significance, least squares mean
pairwise t tests for ‘group by day’ interactions were conducted.
Results
Experiment I
Nasal swabs collected 2 weeks prior to transfection were pooled, while swabs
collected on days 0, 3, 7, 14, and 21 were collected from each nostril (right and left)
separately. DNA extracted from each swab was submitted to Dr. Richard Cooper’s
Laboratory (Louisiana State University, Baton Rouge, LA) for PCR. The cecropin B
gene was not detected by PCR in any calf 2 weeks prior to transfection (Table 3.1).
Table 3.1. Experiment I PCR results. Pre samples taken 2 weeks prior to day 0 were a
pool from both nostrils. All other samples were taken from each nostril.
Calf # Treatment Nostril

Day Post Transfection
Pre
0
3
7
139
E50
R
+
L
145
E50
R
+
+
L
+
+
149
E50
R
L
+
+
151
E50
R
+
+
L
+
+
146
control
R
+
L
148
control
R
+
+
L
+
150
control
R
+
+
L
+
+
E50=calves were given 50 µg of plasmid DNA per nostril

14
+
+
+

21
+
+
+
+
+
-

Positive PCR results were obtained from both treated calves given 50 µg of plasmid
DNA per nostril and control calves after transfection. DNA sequence analysis of PCR
products from both treated and control calves showed these sequences to be identical to
the corresponding amplified regions of the cecropin B gene (data not shown). Positive
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PCR results were obtained from 2 treated calves at day 0 before these calves received the
DNA aerosol. Positive PCR results were obtained from all 4 treated and 2 of 3 control
calves at day 3. Cecropin B DNA was detected in all 7 calves at some point during the
experiment.
Experiment II
Total DNA purified from nasal swabs collected on 0, 3, 7, 14, 21, and 28 days
post transfection/challenge was analyzed by real-time PCR. This real-time PCR assay
was designed to amplify a 76-bp region of the cecropin B gene. For an individual calf the
relative amount of cecropin B DNA in each sample (days 3, 7, 14, 21, and 28) was
determined as a ratio compared to day 0 (the calibrator). The relative amounts of
cecropin B DNA detected on days 3, 7, 14, 21, and 28 in control calves ranged from 1 to
34.6 AU, while calves given 25 µg of plasmid DNA per nostril ranged from 1 to 159.8
AU (Tables 3.2 and 3.3). For all 4 control calves the amount of cecropin B DNA did not
appear to increase after day 0, with one exception (Table 3.2). The amount of cecropin B
DNA detected for calf #158 at day 3 was 34.6 times higher than at day 0. Although
relative amounts of cecropin B DNA that were slightly higher than day 0 were obtained
from all 4 control calves at some point during the experiment, these levels did not appear
to be significant. The amount of cecropin B DNA detected for treated calf #150 at day 3
was 159.8 times higher than at day 0 (Table 3.3). Increased amounts of cecropin B DNA
were also detected in this calf at day 7 and 28. Calf #157 which was given 25 µg of
plasmid DNA per nostril had an increased amount of cecropin B DNA detected at day 3.
However, this level (13.0 AU) is considerably lower than that of treated calf #150 (159.8
AU). Two of the 4 treated calves in this experiment had low levels of cecropin B DNA
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Table 3.2. Real-time PCR, RT-PCR and isolation data of experiment II control calves.
Real-time PCR and RT-PCR results are expressed as arbitrary units (AU).
Calf #

Sample
0

Day Post Transfection/Challenge
3
7
14
21

28

152
cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

1.0
1.0

1.0
1.0

2.8
1.0

1.0
1.0

1.1
1.0

-

+

-

-

-

-

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

1.1
1.6

1.5
ND

1.0
1.0

2.0
1.0

1.0
1.9

-

-

+

-

-

-

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

6.4
1.0

1.0
1.0

1.0
1.0

1.0
1.0

2.3
1.0

-

+

-

-

-

-

34.6
1.0

3.8
1.0

6.5
ND

2.0
1.0

1.1
1.0

+

+

+

+

-

153

155

158
cecropin B DNA 1.0
cecropin B mRNA 1.0
M. haemolytica
isolation
ND= No data; No RNA could be purified

Table 3.3. Real-time PCR, RT-PCR and isolation data of experiment II calves which
received 25 µg of plasmid DNA per nostril. Real-time PCR and RT-PCR results are
expressed as arbitrary units (AU).
Calf #

Sample
0

Day post transfection/challenge
3
7
14
21

28

150
cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

159.8
1.0

18.8
1.0

6
1.0

4
1.0

37.8
1.0

-

+

+

+

-

-

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

13.0
3.9

2.3
772.6

1.4
2.1

2.7
ND

3.4
2.8

-

+

-

+

-

+

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

1.4
1.0

1.0
1.0

1.0
1.0

1.0
1.0

2.3
1.0

-

+

+

+

+

+

1.0
1.0

1.0
1.0

1.0
1.0

1.0
1.0

1.2
1.0

+

+

+

+

-

157

160

161
cecropin B DNA 1.0
cecropin B mRNA 1.0
M. haemolytica
isolation
ND= No data; No RNA could be purified
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comparable with the controls. Comparisons of cecropin B DNA detected in calves within
the 2 groups indicated significant (P<0.05) variation among calves in each group.
Comparisons of cecropin B DNA detected between each group indicated that there was
not significant (P<0.05) variation between the treated and control groups for the entire
duration of the experiment nor between each group at a specific day. Since overall tests
did not indicate significant variation between control calves and calves given 25 µg of
plasmid DNA per nostril no further analyses were performed.
Total RNA purified from nasal aspirates collected on 0, 3, 7, 14, 21, and 28 days
post transfection/challenge was analyzed by real-time RT-PCR. This real-time RT-PCR
assay was designed to amplify a 76-bp region inside the transcribed region of the
cecropin B gene. For an individual calf the relative amount of cecropin B mRNA
expression in each sample (days 3, 7, 14, 21, and 28) was determined as a ratio compared
to day 0 (the calibrator). Relative amounts of cecropin B mRNA detected on days 3, 7,
14, 21 and 28 in control calves ranged from 1 to 1.9 AU, while calves given 25 µg of
plasmid DNA per nostril ranged from 1 to 772.6 AU (Tables 3.2 and 3.3). For all 4
control calves cecropin B mRNA expression did not appear to increase after day 0. For
control calf #158 in which increased levels of cecropin B DNA was detected at day 3, no
increase in mRNA expression was detected at any point of the experiment. Also, for
treated calf #150 no increase in mRNA expression was observed. Increased cecropin B
mRNA expression was only observed in one treated calf. The amount of cecropin B
mRNA expression detected for treated calf #157 at day 7 was 772.6 times higher than at
day 0. No increase in mRNA expression was detected in any other calf given 25 µg of
plasmid DNA at any point of the experiment. Comparisons of cecropin B mRNA
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expression in calves within groups indicated variation approaching significance (P<0.05)
among calves in each group. Comparisons of cecropin B mRNA expression in each
group and each group by day indicated that there was no significant (P<0.05) variation
between groups or between groups by day. Once again, since overall tests did not
indicate significant variation between control calves and calves given 25 µg of plasmid
DNA per nostril no further analyses were performed.
M. haemolytica 1:A was not isolated from any calf at day 0 (Tables 3.2 and 3.3).
However, after challenge, M. haemolytica 1:A was isolated from all calves at some point
during the experiment. M. haemolytica 1:A was isolated from 3 of 4 control calves at day
3, but only 2 of 4 calves from days 7 thru 28. M. haemolytica 1:A was isolated from all 4
calves given 25µg of DNA per nostril at day 3. The bacterium was isolated from all 4 of
these calves at days 7, 14, 21, or 28.
Serum and nasal aspirate titers for all antibody classes were considerably low
(Table 3.4). No differences in serum titers for any class of antibodies were noticed
between control calves and calves given 25 µg of plasmid DNA per nostril. Also, no
differences in nasal aspirate titers for any class of antibodies were noticed between
control calves and calves given 25 µg of plasmid DNA per nostril with one exception.
Nasal aspirate IgA titers against whole M. haemolytica 1:A were detected for 2 of 4
control calves at days 21 and 28, whereas no nasal aspirate IgA titers against whole
M. haemolytica 1:A were detected for any calf given 25 µg of plasmid DNA per nostril.
Again, overall tests indicated no significant (P<0.05) differences between the 2 groups or
between the two groups at any given day post transfection/challenge for any class of
antibody in either serum or nasal aspirates.
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Table 3.4. Mean serum and nasal antibody titers for experiment II calves against whole
M. haemolytica 1:A antigen.
Sample and antibody class
0

Day Post Transfection/Challenge
3
7
14
21

28

Serum
IgG(h &l)
control
E25

0
0

0
0

0.9
1.2

0.5
0.8

0.5
0.4

0.4
0.4

control
E25

0
0

0
0

0
0

0.1
0.1

0.1
0.1

0.1
0.1

control
E25

0
0

0
0

0
0

0.1
0

0.1
0.1

0.1
0.1

control
E25

0
0

0
0

0.2
0.2

0.1
0.1

0.1
0.1

0.1
0.1

control
E25

0
0

0
0

0
0

0
0

0.29
0

0.16
0

control
E25

0
0

0
0

0
0

0
0

0.01
0

0
0

control
E25

0
0

0
0

0
0

0
0

0
0

0
0

control
E25

0
0

0
0

0
0

0.01
0.01

0.01
0

0.01
0

IgG1

IgG2

IgM

Nasal
aspirate

IgG(h &l)

IgG1

IgG2

IgM

IgA
control
0
0
0
0
2.58
1.27
E25
0
0
0
0
0
0
E25=calves were given 25 µg of plasmid DNA per nostril
* Overall test indicated significant (P <0.05) differences between groups, least square
mean pairwise t tests for group by day interactions were performed
† Significantly (P <0.05) greater than mean titer for controls on that day

All calves were examined daily for clinical signs of respiratory disease to
eliminate the possibility of an adventitious infection. However, no evidence of an
adventitious infection was observed.
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Experiment III
Total DNA purified from nasal swabs collected on 0, 3, 7, 14, 21, and 28 days
post transfection/challenge was analyzed by real-time PCR as in experiment II. The
relative cecropin B DNA level of days 3, 7, 14, 21, and 28 as compared with day 0 of
control calves ranged from 0 to 4.6 AU, while calves given 50 µg of plasmid DNA per
nostril ranged from 0 to 988.0 AU (Tables 3.5 and 3.6). The amount of cecropin B DNA
detected in calves given 100 µg of plasmid DNA per nostril ranged from 0 to 9983.1 AU
(Table 3.7). For all 4 control calves the amount of cecropin B DNA did not appear to
increase after day 0 (Table 3.5). For 3 of the 4 calves given 50 µg of plasmid DNA per
nostril increases in cecropin B DNA were detected (Table 3.6). For these calves the
relative amounts of cecropin B DNA ranged from 100.9 to 988.0 AU. For calves given
Table 3.5. Real-time PCR, RT-PCR and isolation data of experiment III control calves.
Real-time PCR and RT-PCR results are expressed as arbitrary units (AU).
Calf #

Sample
0

Day Post Transfection/Challenge
3
7
14
21

28

2189
cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

1.2
3.2

1.6
1.0

1.0
1.0

1.0
1.0

1.0
1.0

-

-

+

-

-

-

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

4.6
1.0

2.6
1.0

4.5
1.0

1.0
ND

1.0
1.0

-

+

+

-

-

-

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

2.3
2.4

1.0
1.0

1.0
1.0

1.0
1.0

1.0
1.0

-

-

+

-

-

-

1.0
1.0

1.0
1.0

1.0
1.0

1.0
ND

1.0
1.0

-

-

-

-

-

2193

2237

2243
cecropin B DNA 1.0
cecropin B mRNA 1.0
M. haemolytica
isolation
ND= No data; No RNA could be purified
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Table 3.6. Real-time PCR, RT-PCR and isolation data of experiment III calves which
received 50 µg of plasmid DNA per nostril. Real-time PCR and RT-PCR results are
expressed as arbitrary units (AU).
Calf #

Sample
0

Day Post Transfection/Challenge
3
7
14
21

28

2013
cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

1.0
12.1

1.0
2.0

1.0
1.0

1.0
1.0

1.0
1.0

-

+

-

-

-

-

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

100.9
148.8

252.2
6.4

2.3
1.0

3.4
ND

3.6
19.6

-

-

-

-

-

-

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

469.0
7.9

5.3
4.3

1.7
1.0

1.5
1.0

1.0
2.3

-

-

-

+

-

-

1.0
7.9

1.0
1.0

1.0
1.0

1.0
1.0

-

-

-

-

2069

2091

2231
cecropin B DNA 1.0
988.0
cecropin B mRNA 1.0
209.1
M. haemolytica
isolation
ND= No data; No RNA could be purified

Table 3.7. Real-time PCR, RT-PCR and isolation data of experiment III calves which
received 100 µg of plasmid DNA per nostril. Real-time PCR and RT-PCR results are
expressed as arbitrary units (AU).
Calf #

Sample
0

Day Post Transfection/Challenge
3
7
14
21

28

2012
cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

2.2
53.1

2.1
78.9

1.0
1.0

1.6
1.0

1.0
1.0

-

-

-

-

-

-

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

1.0
11.0

1.0
1.4

1.0
1.0

1.0
1.0

1.0
1.0

-

-

-

-

-

-

cecropin B DNA
cecropin B mRNA
M. haemolytica
isolation

1.0
1.0

9983.1
6.4

4.8
5.8

5.0
1.0

14.2
ND

13.0
1.0

-

-

-

-

-

-

1.1
1.0

1.1
2.3

1.1
ND

1.0
1.2

-

-

-

-

2027

2077

2178
cecropin B DNA 1.0
1.4
cecropin B mRNA 1.0
150.7
M. haemolytica
isolation
ND= No data; No RNA could be purified
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100 µg of plasmid DNA per nostril, increases in cecropin B DNA were only detected in 1
calf (Table 3.7). At day 3 the relative amount of cecropin B DNA was 9983.1 times
higher than day 0 in calf #2077. Comparisons of cecropin B DNA detected in calves
within the 3 groups indicated significant (P<0.05) variation among calves in each group.
Comparisons of cecropin B DNA detected between each group indicated that there was
not any significant (P<0.05) variation between the treated and control groups for the
entire duration of the experiment or between each group on a specific day. No further
analyses were performed because overall tests did not indicate significant variation
between control calves and the 2 treated groups of calves.
Total RNA purified from nasal aspirates collected on 0, 3, 7, 14, 21, and 28 days
post transfection/challenge was analyzed by real-time RT-PCR as in experiment II. For
all 4 control calves no increase in cecropin B mRNA expression after day 0 was observed
(Table 3.5). Increases in cecropin B mRNA were observed at day 3 in 2 of the 4 calves
given 50 µg of plasmid DNA per nostril (Table 3.6). Likewise, increases in cecropin B
mRNA were observed at day 3 in 2 of the 4 calves given 100 µg of plasmid DNA per
nostril as well (Table 3.7). Comparisons of cecropin B mRNA expression among calves
within the three groups indicated no significance (P<0.05) in variation. However,
comparisons of mean cecropin B mRNA expression between groups and betweens
groups by day indicated that there was significant (P<0.05) variation between the 3
groups. When compared to the control group cecropin B mRNA expression was
significantly (P<0.05) increased in both treated groups at 3 and 7 days post
transfection/challenge (Table 3.8). Analyses were based on least squares means of the
natural log-transformed data, although raw data means were reported.
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Table 3.8. Mean cecropin B mRNA (arbitrary units) detected in calves from experiment
III. Asterisks indicate significant (P<0.05) differences as determined by least squares
means pairwise t test for group by day interactions. Raw means are reported.
Day
Controls
E50
E100
0
1.0
1.0
1.0
3
1.9
94.5*
55.3*
7
1.0
5.2*
21.8*
14
1.0
1.0
1.3
21
1.0
1.0
1.0
28
1.0
6.0
1.1
E50=calves were given 50 µg of plasmid DNA per nostril
E100=calves were given 100 µg of plasmid DNA per nostril

ELISA was used to detect cecropin B in nasal aspirates collected on 0, 3, 7, 14,
21, and 28 days post transfection/challenge. Cecropin B was detected in all calves at day
0 (Figure 3.1). A significant (P<0.05) increase in the mean amount of cecropin B

cecropin B (ng/ml)

detected in the 2 groups of calves given 50 µg or 100 µg of plasmid DNA per nostril was
*

60

*

control

40

E50
20

E100

0
0

3

7

14

21

28

Day Post Transfection/Challenge

E50=calves were given 50 µg of plasmid DNA per nostril
E100=calves were given 100 µg of plasmid DNA per nostril
* Significantly (P <0.05) greater than mean cecropin B
detected for controls at that day

Figure 3.1. Mean cecropin B peptide detection by ELISA. Results are expressed in
ng/ml amounts.
observed between days 7 and 14. Furthermore, mean cecropin B detected in calves given
50 µg or 100 µg of plasmid DNA per nostril was significantly (P<0.05) greater than
mean amounts detected in the control calves at day 14. Mean amounts of peptide
detected in these 2 treated groups at day 14 were not significantly different (P<0.05) from
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each other, although slightly higher amounts of cecropin B were detected in calves given
50 µg of plasmid DNA per nostril. For all calves cecropin B detection dropped at days
21 and 28. This decrease in peptide was only statistically significant (P<0.05) for the 2
treated groups.
M. haemolytica 1:A was not isolated from any calf at day 0 (Tables 3.5, 3.6, and
3.7). However, after challenge M. haemolytica 1:A was isolated from 3 of 4 control
calves at some point during the experiment (Table 3.5). At day 3 M. haemolytica 1:A
was isolated from only 1 of 4 (by enrichment media) calves given 50 µg of plasmid DNA
per nostril, and from only one other calf in this group on day 14 (Table 3.6). M.
haemolytica 1:A was not isolated from any of the 4 calves given 100 µg of plasmid DNA
per nostril at any point of the experiment (Table 3.7).
Serum and nasal aspirate titers for all antibody classes were considerably higher
than those of the experiment II calves (Table 3.9). Serum titers for all classes of antibody
and all 3 groups peaked at day 21. Serum antibody titers for all classes against whole M.
haemolytica 1:A were higher for calves given 50 µg of plasmid DNA per nostril than
control calves and calves given 100 µg of plasmid DNA per nostril. No differences in
serum titers for any class of antibody were noticed between control calves and calves
given 100 µg of plasmid DNA per nostril with one exception. Serum IgG1 titers against
whole M. haemolytica 1:A were slightly higher for calves given 100 µg of plasmid DNA
per nostril than titers for control calves. The nasal aspirate IgG (h & l), IgG1, IgG2, and
IgM titers against whole M. haemolytica 1:A for the 3 groups were relatively equal. The
nasal aspirate IgA titers for control calves appeared to be higher than calves given 50 µg
or 100 µg of plasmid DNA per nostril. The nasal aspirate IgA titers against whole
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Table 3.9. Mean serum and nasal antibody titers for experiment III calves against whole
M. haemolytica 1:A antigen.
Sample and antibody class
0

Day Post Transfection/Challenge
3
7
14
21

28

Serum
IgG(h &l)*
control
E50
E100

0.1
0.1
0.1

0.1
0.1
0.1

18.1
†
84.1
14.9

41.1
†
118.5
49.9

47.4
†
135.1
74.2

47.8
†
122.4
56.3

control
E50
E100

0.1
0
0

0.1
0
0

8.8
†
24.4
8.7

16.4
†
41.8
26.1

25
†
63.5
32.6

23.3
†
51.3
25.4

control
E50
E100

0
0
0

0
0
0

1
2.8
0.1

3.4
6.3
2.6

9.6
14.7
9

6.2
11.6
6.3

control
E50
E100

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

control
E50
E100

0.13
0.02
0.36

0.06
0
0

0.03
0.18
0.02

0.02
0.04
0.02

0.61
0.71
0.38

0.36
0.53
0.21

control
E50
E100

0.01
0
0

0.01
0
0

0.01
0.02
0.01

0.01
0.01
0.01

0.01
0.01
0.01

0.01
0.03
0.01

control
E50
E100

0.01
0
0

0.01
0.01
0

0
0
0

0
0
0

0.01
0
0

0.01
0.01
0

control
E50
E100

0
0
0

0
0
0

0.01
0.01
0.01

0.01
0
0

0.01
0.01
0.01

0.01
0.01
0.01

IgG1*

IgG2

IgM

Nasal
aspirate

IgG(h &l)

IgG1

IgG2

IgM

IgA
control
0.99
1.16
1.21
0.47
5.62
3.15
E50
0.03
0
0.67
0.46
3.28
0.12
E100
1.17
0
0
0
0.84
0.36
E50=calves were given 50 µg of plasmid DNA per nostril
E100=calves were given 100 µg of plasmid DNA per nostril
* Overall test indicated significant (P <0.05) differences between groups, least square
mean pairwise t tests for group by day interactions were performed
† Significantly (P <0.05) greater than mean titer for controls on that day

72

M. haemolytica 1:A for calves given 50 µg of plasmid DNA per nostril were also slightly
higher than calves given 100 µg of DNA per nostril.
Overall tests indicated no significant (P<0.05) differences between each group or
between each group at any given day for any class of antibody in nasal aspirates, but only
for IgG2 and IgM titers in serum. Tests indicated that there was significant (P<0.05)
variation between groups by day, while variation between groups for the entire
experiment were approaching significance. Least squares means pairwise t test for group
by day interactions indicated that mean serum IgG (h & l) and IgG1 titers for calves given
50 µg of plasmid DNA per nostril were significantly (P<0.05) greater than mean titers for
the control group and the group of calves given 100 µg of plasmid DNA per nostril at 7
thru 28 days post transfection/challenge (Table 3.9). Mean serum IgG (h & l) and IgG1
titers for calves given 100 µg of plasmid DNA per nostril were not significantly (P<0.05)
different than mean titers for the control group at any point of the experiment.
All calves were examined daily for clinical signs of respiratory disease to
eliminate the possibility of an adventitious infection. Again, no evidence of an
adventitious infection was observed.
Discussion
Previous studies have demonstrated the possible use of antibacterial peptides such
as cecropin B as topical or injectable antibiotics against pathogens otherwise resistant to
conventional antibiotics (Hancock et al., 1998). However, cost of production may limit
this peptide’s usefulness. The most cost efficient peptide synthesis methods employed at
the present time are still unreasonably expensive (Hancock et al., 1998). One possible
cost-effective approach would be to transfer the cecropin B gene into the species of
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interest, and let the recipient’s biosynthesis mechanisms synthesize the peptide. Most
gene transfer studies involving the cecropin B gene or genes of cecropin B homologues
and analogues have been performed in plants and fish, but also in mice and oysters
(Buchanan et al., 2001, Chiou et al., 2002, Dunham et al., 2002, Hagius et al., 1996,
Hancock et al., 1998, Sarmasik et al., 2002, Zhang et al., 1998). These studies have met
with some success. Most show that cecropin B can be expressed at the RNA and protein
level, while displaying some bacterial resistance.
Results of experiment I indicate that the cecropin B gene can be detected in DNA
extracted from nasal swabs collected from transfected calves. Furthermore, the cecropin
B gene could be detected for at least 3 weeks post transfection. From this data it seems
obvious that aerosolization using the previously described methods was successful in
depositing the gene into the nasal passage of calves.
Detection of the cecropin B gene at day 0 prior to these calves being transfected
and in untreated control calves could implicate the possible presence of a native bovine
cecropin or cecropin-like gene. However, transmission of the gene can not be ruled out.
Indeed, studies suggest that cecropins may be widespread throughout the animal kingdom
(Boman et al., 1991, Hancock et al., 1998, Marshall and Arenas, 2003). A cecropin was
found in the upper part of the porcine small intestine (Lee et al., 1989). Cecropins
contribute to the animal’s innate immunity in every species in which they have been
found. As of this study no bovine cecropin has been identified. Many other
antimicrobial peptides have been found in cattle including cathelicidins, lactoferricins,
and the β-defensin, Tracheal Antimicrobial Peptide (TAP), among others (Diamond et al.,
2000, Haukland et al., 2001, Huttner et al., 1998b). Most of these peptides are very
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different from cecropins; for example TAP and the cathelicidins contain several cysteine
residues which form disulfide bonds. Cecropins are cysteine-free peptides.
It is also possible that the cecropin B gene was transmitted from treated to control
calves. No cecropin B DNA was detected in any experiment I calf two weeks prior to
transfection. Also, no cecropin B DNA was detected in the 3 control calves on day 0.
Swabs were collected from these calves before any aerosolization of plasmid DNA, then
the calves were allowed to return to pasture. The 4 treated calves were sampled, then
immediately aerosolized with plasmid DNA one at a time with the remaining calves in
the chute right behind them. It could be possible that some of the plasmid DNA
aerosolized escaped into the air and contaminated subsequent calves. Unfortunately no
records were kept as to the order in which calves were sampled and transfected.
Following transfection all treated calves were allowed to return to pasture with the
controls where transmission could have occurred. To reduce the possibility of
transmission, groups in experiments II and III remained isolated from each other.
Furthermore, all calves were sampled before aerosolization of plasmid DNA, and treated
calves were aerosolized alone in the chute. Researchers wore protective equipment.
The real-time PCR and RT-PCR assays were designed to quantify cecropin B
DNA and mRNA detected. The primers and fluorescent dye-labeled probe were
designed to amplify a specific 76-bp region of the cecropin B gene. This sequence is
inside the transcribed region of the gene. Without a pure control containing a known
number of cecropin B gene copies, absolute quantitations could not be performed.
Relative quantitations are easy to perform because quantity is expressed relative to some
basis sample (i.e. the calibrator). Quantity is determined from the standard curve and

75

then divided by the quantity of the calibrator. Here, quantitation was based on 5-fold
serial dilutions of bovine DNA spiked with the cecropin B gene. For an individual calf
the relative quantitation at days 3, 7, 14, 21, and 28 was determined as a ratio compared
to day 0. Day 0 results were designated as the calibrator for each calf. Each calf’s day 0
quantity was arbitrarily chosen as its calibrator because it would be expected to have the
lowest expression level of the target. The day 0 quantities became the 1x sample,
therefore arbitrary units (AU) can be read as an n-fold increase in either cecropin B DNA
or cecropin B mRNA expression. Hence, 3.0 AU of cecropin B mRNA at day 3 would
indicate that cecropin B mRNA expression was 3.0 times higher than at day 0. While
300.0 AU of mRNA at day 3 would indicate that cecropin B mRNA expression was
300.0 times higher than at day 0.
The measurement of cecropin B DNA following transfection provided an
indication of the longevity of the gene. Following transfection the plasmid was either
cleared from the mucosa or delivered to cells where the gene was stably inserted into the
genome. In both experiments II and III the cecropin B gene could be detected even at 28
days post transfection. In most cases these DNA levels were comparable with the levels
detected in controls. Once again the detection of cecropin B DNA in untreated calves
could be due to a native bovine cecropin, therefore it is unclear whether or not levels of
cecropin B DNA detected in transfected calves at 4 weeks is a persistence of the
transferred gene. Further research may be necessary to determine the longevity of
transfection.
In all 3 treated groups of calves there was significant variation in the amounts of
cecropin B DNA detected, but no significant differences were observed between treated
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groups and their respective control groups. Although increased amounts of cecropin B
DNA were detected in some individual calves from each of the 3 treated groups, the data
appeared to be statistically insignificant. However, levels of cecropin B DNA detected in
those treated calves was noticeably higher than any control calf indicating some
difference between control and treated calves. Perhaps using larger numbers of test
calves would validate these findings.
Results of experiment II indicate that an aerosol of 25 µg of plasmid DNA per
nostril was not enough to consistently transfect calves. An increase in cecropin B mRNA
expression was detected in only one calf given 25 µg of plasmid DNA per nostril.
Whereas this level of expression was higher than any of the experiment III treated calves,
this result appeared to be statistically insignificant. Furthermore, M. haemolytica 1:A
was isolated more frequently from calves given 25 µg of plasmid DNA per nostril than
any other group in experiments II or III. Even if increased mRNA expression went
undetected in these calves it did not provide protection against M. haemolytica 1:A
following challenge.
Results of experiment III mean cecropin B mRNA expression comparisons
between the treated and control groups indicated that significant differences existed
between the 3 groups. When compared to the control group cecropin B mRNA
expression was significantly increased in calves given 50 µg or 100 µg of plasmid DNA
per nostril at 3 and 7 days post transfection. The highest levels of cecropin B mRNA
were achieved in most calves at day 3, and expression appeared to decline in these calves
between days 3 and 7. Analyses were based on least squared means of the natural logtransformed data, although raw data means were reported.

77

ELISA was then used to detect cecropin B peptide in nasal aspirates collected
from experiment III calves. Cecropin B was detected in all calves at day 0. Once again
this implies the presence of native bovine cecropin. However, a significant increase in
the mean amount of cecropin B detected in the 2 groups of calves given 50 µg or 100 µg
of plasmid DNA per nostril was observed at day 14, while no such increase was observed
in the control calves. Mean amounts of the peptide detected in these 2 treated groups at
day 14 were not significantly different from each other, although slightly higher amounts
of cecropin B were detected in calves given 50 µg of plasmid DNA per nostril. For all
calves in experiment III, cecropin B peptide detection dropped at days 21 and 28. These
suspicious ELISA results were repeated and validated.
Evidence has shown that the cecropin B activity is dependent on the concentration
of cecropin (Boman et al., 1991). Binding sufficient amounts of cecropin to form a
monolayer is necessary to modify the bacterial membranes (Steiner et al., 1988).
Bacteria which are resistant to cecropin still bind large amounts in a non-productive
manner, indicating that cecropins act stoichiometrically. The activity of cecropin B is a
matter of mass action, and is not catalytic in nature (Steiner et al., 1988). Hence, more
peptide is required to kill more bacteria. If mRNA and subsequent peptide production
was halted, then a decline in available cecropin B peptide would occur. The drastic
decline in cecropin B detection at days 21 and 28 is likely a result of all available peptide
being sequestered to kill bacteria, while no more peptide was being produced.
The raw data showed that expression of cecropin B at the mRNA and protein
level appeared to be more consistent among calves given 50 µg of plasmid DNA per
nostril than among calves given 100 µg of plasmid DNA per nostril. Certainly mean
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cecropin B mRNA and peptide expression levels were higher in calves given 50 µg of
plasmid DNA per nostril. However these levels were not found to be significantly
different from calves given 100 µg of plasmid DNA per nostril. Protection against
challenge with a virulent stain of M. haemolytica 1:A seemed more apparent in calves
given 100 µg of plasmid DNA per nostril where M. haemolytica 1:A was not isolated
from any calf at any point during the experiment. M. haemolytica 1:A was isolated from
2 of the 4 calves given 50 µg of plasmid DNA per nostril. It should be noted that M.
haemolytica 1:A was not isolated from the 2 calves given 50 µg of plasmid DNA per
nostril in which the highest levels of cecropin B mRNA and peptide expression were
detected.
Further differences between the 3 groups of experiment III can be seen in serum
and nasal aspirate antibody titers against whole M. haemolytica 1:A antigen. Serum IgG
(h & l), IgG1, and IgG2 titers were consistently higher in calves given 50 µg of plasmid
DNA per nostril, while these titers detected in control calves and calves given 100 µg of
plasmid DNA per nostril did not appear to differ. In contrast higher IgA antibody titers
in nasal aspirates were achieved in control calves. This trend was also observed in
experiment II where IgA titers were higher in control calves than calves which received
25 µg of plasmid DNA per nostril. In neither experiment were these IgA titers shown to
be statistically significant, nevertheless the trend was observed. It would appear that in
the absence of peptide, M. haemolytica 1:A antigens were more readily available for IgA
production. No sound explanation for consistently higher serum IgG (h & l), IgG1, and
IgG2 antibody titers in calves given 50 µg of plasmid DNA per nostril can be offered.
However, mean cecropin B mRNA and peptide expression levels were highest in calves
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given 50 µg of plasmid DNA per nostril. Perhaps in these calves inhibition of M.
haemolytica 1:A eased phagocytosis and enhanced antibody production. However this
would not explain why titers detected in control calves and calves given 100 µg of
plasmid DNA per nostril did not appear to differ.
Antibody titers against whole M. haemolytica 1:A antigen at day 0 (before
challenge) were likely the result of prior exposure to M. haemolytica 1:A. These findings
were consistent with the results of a previous study (Brennan et al., 1998). These titers
were not believed to affect the data collected since they were measured to detect
differences in antibody production between control and treated groups, not to determine
the efficacy of treatments on antibody production.
Very few studies are available describing transfected mammals expressing
cecropin B or cecropin B-like peptides. In a preliminary report researchers using a
cecropin B analog to transfect mice found the mice to be resistant to Brucella abortus, a
bovine pathogen (Hagius et al., 1996). There are many indications that a transgenic or
gene therapeutic approach may be useful in enhancing bacterial resistance in food
animals, thereby reducing the use of conventional antibiotics. Results of this study show
that calves transfected with sufficient copies of the cecropin B gene can express cecropin
B at the RNA and protein level, while displaying some resistance to M. haemolytica 1:A.
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CHAPTER 4
CHANGES IN THE NORMAL AND TRANSIENT NASAL FLORA OF CALVES
TRANSFECTED WITH A GENE CODING FOR CECROPIN B

Introduction
Although Pasteurella multocida and Haemophilus somnus have been associated
with Bovine Respiratory Disease (BRD), the major etiologic agent of bovine pneumonic
pasteurellosis is Mannheimia haemolytica 1:A (Dalgleish, 1990, Frank, 1986). M.
haemolytica serotype 1, biotype A (formally known as Pasteurella haemolytica 1:A) is a
nonmotile, Gram-negative coccobacilli or rod, and a facultative anaerobe. M.
haemolytica 1:A is considered to be part of the transient bacterial flora in the upper
respiratory tract (URT) of clinically healthy cattle, and can exist in the nasal cavity in
very low numbers (Carter et al., 1991, Whiteley et al., 1992).
In addition to M. haemolytica, Pasteurella Multocida, and Haemophilus somnus,
the bacteria commonly associated with BRD, the nasal passage of cattle is home to a
diverse collection of bacteria that make up the normal and transient flora. Although a
complete listing of all the bacteria found in the nasal passage of cattle does not appear to
have been reviewed recently, there are some organisms mentioned in the literature. Some
prominent bacteria found in the URT include Gram-positive bacteria such as
Micrococcus, Corynebacterium, Staphylococcus, Streptococcus, and Bacillus as well as
Gram-negative bacteria such as Pseudomonas, Actinobacter, Moraxella, Neisseria
catarrhalis, and Escherichia coli (Corbeil et al., 1985, Woldehiwet et al., 1990). Other
members of the bovine nasal flora may include Gram-positive bacteria such as
Lactobacillus, Streptomyces, and Diplococcus pneumoniae as well as Gram-negative
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bacteria such as Chromobacterium, Achromobacter, Serratia, Flavobacterium, Proteus,
and Klebsiella (Magwood et al., 1969). These species of bacteria have been found to
start colonizing the URT as early as the calf’s first day of life (Woldehiwet et al., 1990).
The total bacterial load in the nasal passage increases with age, and is influenced by
environmental temperature (Woldehiwet et al., 1990). The purpose of this study was to
ascertain whether or not transfecting the URT of cattle with a gene coding for cecropin B
would result in a change in the indigenous and transient flora.
Materials and Methods
Nasal aspirates collected from experiment II and III calves on 0, 3, 7, 14, 21, and
28 days post challenge (DPC) were analyzed by bacterial culture. Aliquots of these
samples were diluted in sterile duPBS to 1:10, 1:100, and 1:1000 of the original
concentration. Within one to four hours after collection, small amounts (0.1 ml) of each
dilution and of the undiluted sample were directly plated onto separate 1% yeast blood
agar plates (YBP) (Difco, Becton, Dickinson and Co., Sparks, MD.). The plates were
allowed to incubate in a 5% CO2 atmosphere for up to 72 hours at 37oC. The plates were
observed for bacterial growth every 24 hours. Isolated colonies of M. haemolytica 1:A as
well as the calves’ bacterial flora were counted, identified, and recorded.
Small amounts (0.1 ml) of the undiluted sample were inoculated into Difco
thioglycollate enrichment medium (Becton, Dickinson and Co., Sparks, MD.) plus 0.1%
horse serum. The thioglycollate tubes were allowed to incubate for up to 72 hours at
37oC. The tubes were observed for bacterial growth every 24 hours. Observed growth
was then recorded and streaked onto 1% YBP, which were incubated in a 5% CO2
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atmosphere for 24 hours at 37oC. Isolated colonies of M. haemolytica 1:A as well as the
calves’ bacterial flora were identified and recorded.
Pure cultures for representative colonies of all macroscopically different types
were first identified on the basis of colonial morphology. These representative colonies
were then streaked onto manitol salt and McConkey agar plates as well as triple sugar
iron (TSI), citrate, and urea slants (Difco, Becton, Dickinson and Co., Sparks, MD.).
Smears of these representative colonies were also Gram (Difco, Becton, Dickinson and
Co., Sparks, MD.) stained. Bacteria were identified on the basis of morphological,
cultural, and biochemical characteristics of the isolates in pure culture. Coccus shaped
bacteria were further identified by catalase (H2O2) test. Suspected M. haemolytica 1:A
colonies were further identified by the presence of hemolysis, as well as an agglutination
and oxidase (Difco, Becton, Dickinson and Co., Sparks, MD.) test. All findings were
recorded.
Results
During the summer months of experiment II, M. haemolytica 1:A was not isolated
from any calf at day 0 (Tables 4.1 and 4.2). However, after challenge M. haemolytica
1:A was isolated from all calves at some point during the experiment. M. haemolytica
1:A was isolated from 3 of 4 control calves at day 3, but only 2 of 4 calves from days 7
thru 28. M. haemolytica 1:A was isolated from all 4 calves given 25 µg of plasmid DNA
per nostril at day 3. M. haemolytica 1:A was also isolated from all 4 of these calves at
either days 7, 14, 21, or 28.
During the fall months of experiment III, M. haemolytica 1:A was not isolated
from any calf at day 0 (Tables 4.3-4.5). However, after challenge M. haemolytica 1:A
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Table 4.1. Summary of bacteria (CFU) isolated on direct media from experiment II control calves.
CALF #
DAY

158
5

153

155
4

152
4

0

2.5x10 Micrococcus spp.

7000 Corynebacterium spp.
400 Micrococcus spp.

6x10 Achromobacter spp.
>1x104 Micrococcus spp.

6x10 Corynebacterium spp.

3

2.5x105 Mannheimia
haemolytica*

2750 Corynebacterium spp.
100 Bacillus spp.

1.9x104 M. haemolytica
300 Micrococcus spp.

7x104 M. haemolytica*
1.1x105 Micrococcus spp.
2000 Streptococcus spp.

7

3.1x104 Corynebacterium spp.
2.1x105 M. haemolytica

1000 Gram (-) coccus**
1250 M. haemolytica

1050 Corynebacterium spp.
100 Staphylococcus spp.

No isolations

14

100 Bacillus spp.
100 Escherichia spp.
3000 M. haemolytica*
100 Micrococcus spp.

1000 Bacillus spp.
1000 Escherichia spp.
1x104 Micrococcus spp.
4500 Streptococcus spp.

No isolations

No isolations

21

300 Bacillus spp.
3.5x104 M. haemolytica
5500 Streptococcus spp.

4000 Corynebacterium spp.
3650 Streptococcus spp.
5x104 Streptomyces spp.

1000 Bacillus spp.
400 Corynebacterium spp.
100 Escherichia spp.

600 Bacillus spp.
2x104 Escherichia coli
7133 Streptococcus spp.

28

7000 Achromobacter spp.
200 Micrococcus spp.

1x104 Corynebacterium spp.

100 Achromobacter spp.
300 Micrococcus spp.

300 Bacillus spp.
800 Micrococcus spp.

*Also isolated from enrichment media
**Unable to identify
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Table 4.2. Summary of bacteria (CFU) isolated on direct media from experiment II calves that were given 25 µg of plasmid DNA per
nostril.
CALF #
DAY

150

157

160

161

0

4.3x105 Acinetobacter spp.

2.8x106 Pseudomonas spp.

1x106 Micrococcus spp.
1x105 Pseudomonas spp.

1.2x105 Corynebacterium spp.
>1x106 Pseudomonas spp.

3

1000 Corynebacterium spp.
1x105 Mannheimia
haemolytica
2000 Micrococcus spp.

5.8x104 M. haemolytica*

1.6x104 M. haemolytica*

1.6x104 M. haemolytica
3200 Micrococcus spp.
100 Staphylococcus spp.

7

2.1x104 Corynebacterium spp.
4x105 Escherichia spp.
2.8x105 M. haemolytica

4000 M. haemolytica

4x104 Escherichia coli
2.9x105 M. haemolytica

14

3000 Achromobacter spp.
1x104 Gram (-) coccus**
400 M. haemolytica*
5500 Streptococcus spp.

3x104 Achromobacter spp.
1000 Corynebacterium spp.
2.3x104 Lactobacillus spp.
1.2x104 Staphylococcus spp.
6x104 M. haemolytica*
100 Micrococcus spp.

200 Bacillus spp.
3.4x104 M. haemolytica
2x104 Micrococcus spp.
6x104 Streptococcus spp.

1.4x104 Corynebacterium spp.
5x104 M. haemolytica
2x104 Micrococcus spp.

21

4x104 Achromobacter spp.
1000 Bacillus spp.
7500 Escherichia spp.

4000 Alcaligenes spp.
4750 Escherichia spp.
200 Micrococcus spp.

1.6x104 Bacillus spp.
6x104 Corynebacterium spp.
6000 E. coli
1.7x104 M. haemolytica

550 Bacillus Spp.
9.4x104 Corynebacterium spp.
100 E. coli
1x104 M. haemolytica*

3x104 M. haemolytica

2x104 Achromobacter spp.
1200 M. haemolytica*

2.6x105 Corynebacterium spp.
1050 Micrococcus spp.

3.2x105 Achromobacter spp.
650 Micrococcus spp.
*Also isolated from enrichment media
**Unable to identify
28
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Table 4.3. Summary of bacteria (CFU) isolated on direct media from experiment III control calves.
CALF #
DAY

2193

2189

2237

4

2243
4

0

500 Corynebacterium spp.
100 Bacillus spp.
300 Micrococcus spp.

4x10 Corynebacterium spp.
1750 Bacillus spp.
4.3x104 Micrococcus spp.

750 Corynebacterium spp.
400 Bacillus spp.

6.8x10 Corynebacterium spp.
400 Bacillus Spp.

3

650 Corynebacterium spp.
5000 Mannheimia
haemolytica
100 Streptococcus spp.

2750 Achromobacter spp.

2.4x105 Corynebacterium spp.
1700 Bacillus spp.
2200 Escherichia spp.

4.6x104 Corynebacterium spp.
200 Streptococcus spp.

7

650 Achromobacter spp.
650 Corynebacterium spp.
1000 M. haemolytica

200 Achromobacter spp.
600 Corynebacterium spp.
2850 M. haemolytica

3x104 Achromobacter spp.
1.2x105 Corynebacterium spp.
6.5x104 M. haemolytica
600 Micrococcus spp.

5x104 Corynebacterium spp.
200 Micrococcus spp.
300 Streptococcus spp.

14

400 Corynebacterium spp.
700 Micrococcus spp.

1200 Streptomyces spp.

1.6x104 Corynebacterium spp.
2000 Bacillus spp.
1000 Micrococcus spp.

900 Streptomyces spp.

21

5200 Micrococcus spp.

1.3x105 Micrococcus spp.

1.1x105 Corynebacterium spp.
1900 Micrococcus spp.

8000 Corynebacterium spp.
5300 Micrococcus spp.

28

5.5x104 Corynebacterium spp.
1100 Staphylococcus spp.

600 Coliform spp.*
1.1x105 Corynebacterium spp.
100 Bacillus spp.
3x104 Micrococcus spp.

1.2x105 Corynebacterium spp.
3350 Micrococcus spp.

7.8x104 Corynebacterium spp.
1.1x105 Micrococcus spp.

*Unable to identify
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Table 4.4. Summary of bacteria (CFU) isolated on direct media from experiment III calves that were given 50 µg of plasmid DNA
per nostril.
CALF #
DAY

2231

2013

2091

2069

0

1.7x104 Corynebacterium pp.
200 Bacillus spp.
1.2x104 Micrococcus spp.

5.5x104 Corynebacterium spp.
6500 Micrococcus spp.

3100 Corynebacterium spp.
300 Bacillus spp.
2500 Micrococcus spp.

300 Corynebacterium spp.
400 Bacillus spp.
300 Micrococcus spp.

3

500 Achromobacter spp.
3.7x104 Corynebacterium spp.
100 Bacillus spp.

2000 Achromobacter spp.
1950 Corynebacterium spp.
400 Streptococcus spp.
Mannheimia haemolytica*

100 Corynebacterium spp.
5350 Micrococcus spp.
100 Streptococcus spp.

500 Achromobacter spp.
100 Bacillus spp.
2000 Micrococcus spp.
400 Streptococcus spp.

7

1.7x104 Achromobacter spp.
5300 Corynebacterium spp.
200 Streptococcus spp.

1.6x104 Corynebacterium spp.
100 Micrococcus spp.

5.7x104 Corynebacterium spp.

2500 Achromobacter spp.
1100 Corynebacterium spp.

14

9500 Corynebacterium spp.
550 Micrococcus spp.

3.1x105 Corynebacterium spp.
300 Micrococcus spp.

5366 Corynebacterium spp.
4050 Bacillus spp.
4x104 M. haemolytica**

2.4x104 Corynebacterium spp.
100 Bacillus spp.

21

2.2x104 Corynebacterium spp.
100 Micrococcus spp.

7.1x104 Corynebacterium spp.
200 Micrococcus spp.

5500 Corynebacterium spp.

2600 Corynebacterium spp.
100 Bacillus spp.

28

4.3x104 Corynebacterium spp.

5.3x104 Corynebacterium spp.

2200 Corynebacterium spp.
4x104 Micrococcus spp.

5.2x104 Corynebacterium spp.
100 Bacillus spp.
300 Micrococcus spp.

*Isolated from enrichment media, but not direct; no colony count
**Also isolated from enrichment media
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Table 4.5. Summary of bacteria (CFU) isolated on direct media from experiment III calves that were given 100 µg of plasmid DNA
per nostril.
CALF #
DAY

2027

2178

2077

5

4

2012

0

1200 Corynebacterium spp.
200 Bacillus spp.

1.6x10 Achromobacter spp.
2x104 Micrococcus spp.

8.5x10 Corynebacterium spp.
2200 Escherichia spp.
4.5x104 Micrococcus spp.

1000 Corynebacterium spp.
500 Micrococcus spp.

3

600 Achromobacter spp.
2x104 Corynebacterium spp.

700 Corynebacterium spp.
300 Micrococcus spp.

400 Achromobacter spp.
100 Corynebacterium spp.
2x104 Micrococcus spp.

2950 Achromobacter spp.
1550 Corynebacterium spp.
100 Bacillus spp.

7

6.5x104 Corynebacterium spp.
300 Micrococcus Spp.

8400 Corynebacterium spp.
1000 Micrococcus spp.
100 Streptococcus spp.

4000 Achromobacter spp.
6750 Corynebacterium spp.
100 Streptococcus spp.

1x104 Corynebacterium spp.
100 Bacillus spp.
100 Micrococcus spp.
100 Streptococcus spp.

14

5000 Corynebacterium spp.
650 Micrococcus spp.
3x104 Pseudomonas spp.

600 Corynebacterium spp.
100 Micrococcus spp.

300 Micrococcus spp.

5x105 Corynebacterium spp.
1.4x104 Micrococcus spp.

21

3.8x105 Corynebacterium spp.
100 Bacillus spp.

1050 Corynebacterium spp.
100 Bacillus spp.
600 Micrococcus spp.

7050 Corynebacterium spp.
100 Bacillus spp.

1.7x105 Corynebacterium spp.
100 Bacillus spp.
2400 Micrococcus spp.

28

2.6x105 Corynebacterium spp.
1x104 Bacillus spp.
1400 Micrococcus spp.

8x105 Corynebacterium spp.

1000 Corynebacterium spp.
900 Bacillus spp.
4x105 Micrococcus spp.

3x105 Corynebacterium spp.
100 Bacillus spp.
800 Micrococcus spp.
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was isolated from 3 of 4 control calves at some point during the experiment. M.
haemolytica 1:A was isolated from only 1 of 4 (by enrichment media) calves given 50 µg
of plasmid DNA per nostril at day 3, and only 1 of 4 calves from days 7 thru 28. M.
haemolytica 1:A was not isolated from any of the 4 calves given 100 µg of plasmid DNA
per nostril at any point in the experiment.
After challenge M. haemolytica 1:A was isolated a total of 38 times from all five
groups. The organism was isolated 28 times on direct media and 10 times in enrichment
media. Many times it was isolated on both direct and enrichment media, only once was it
isolated solely in enrichment media. M. haemolytica 1:A was isolated with a 29%
frequency from experiment II control calves and a 63% frequency from calves given 25
µg of plasmid DNA per nostril (Figure 4.1). M. haemolytica 1:A was the most frequently
isolated organism from calves given 25 µg of plasmid DNA per nostril. However, M.
haemolytica 1:A was only isolated with a 17% frequency from experiment III control
calves and a 8% frequency from calves given 50 µg of plasmid DNA per nostril. Again
M. haemolytica 1:A was not isolated from any calf given 100 µg of plasmid DNA per
nostril.
Bacteria isolated from both summer and fall experiments on direct and
enrichment media include Achromobacter, Pseudomonas, Micrococcus,
Corynebacterium, Bacillus, Streptococcus, and more (Tables 4.1-4.5, Figure 4.1).
Escherichia coli was isolated several times from both groups in experiment II, but was
never isolated during experiment III. Other Escherichia species were isolated during both
experiments, but were isolated more frequently during experiment II (Figure 4.1). An
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Experiment II
controls

Experiment II
25 µg/nostril

Experiment III
controls

Experiment III
50 µg/nostril

Experiment III
100 µg/nostril

Mannheimia 1:A
haemolytica

Experiment II
controls

Experiment II
25 µg/nostril

Experiment III
controls

Experiment III
50 µg/nostril

Experiment III
100 µg/nostril

Flavobacterium spp.

29%

63%

17%

8%

0%

Achromobacter spp.

0%

0%

0%

4%

0%

50%

42%

67%

63%

75%

38%

33%

83%

96%

92%

33%

17%

50%

50%

46%

25%

8%

17%

17%

13%

4%

8%

4%

4%

0%

4%

0%

8%

0%

0%

4%

8%

0%

0%

0%

4%

0%

0%

0%

0%

Micrococcus spp.

17%

21%

17%

21%

21%

Acinetobacter spp.

Corynebacterium spp.

0%

4%

0%

0%

0%

Pseudomonas spp.

Baccilus spp.

0%

13%

0%

0%

4%

Alcaligenes spp.

Streptococcus spp.

0%

4%

0%

0%

0%

Escherichia coli

Staphylococcus spp.

17%

17%

0%

0%

0%

Escherichia spp.

Streptomyces

17%

25%

4%

0%

4%

Coliform*

Lactobaccilus spp.

0%

0%

13%

0%

0%

Gram-negative
coccus*

Peptococcus spp.

4%

4%

0%

0%

0%

Citrobacter spp.
KEY:
DAY
4%

4%

0%

0%

0%

CALF
1
2
3
4

Chromobacter spp.

0%

4%

0%

0%

0%

0

3

7 14 21 28

ISOLATIONS:
NEGATIVE
POSITIVE
% FREQUENCY

*Unable to identify

Figure 4.1. Frequency of bacterial isolations from nasal aspirates on direct and enrichment media
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unidentifiable Gram-negative coccus was isolated once from an experiment II control calf
(Table 4.1) and once from a calf given 25 µg of plasmid DNA per nostril (Table 4.2). An
unidentifiable coliform was isolated on direct media once from an experiment III control
calf (Table 4.3) and twice on enrichment media from 2 different experiment III control
calves.
Percent frequency of the nasal flora isolations were different between experiments
II and III, but were consistent among the groups in each experiment (Figure 4.1).
Micrococcus spp. were the most frequently isolated organisms in experiment II.
Micrococcus spp. were isolated with a 50% frequency from experiment II control calves
and a 42% frequency from calves given 25 µg of plasmid DNA per nostril. In experiment
III, Micrococcus spp. were isolated with an 67% frequency from experiment III control
calves, a 63% frequency from calves given 50 µg of plasmid DNA per nostril and a 75%
frequency from calves given 100 µg of plasmid DNA per nostril. Corynebacterium spp.
were isolated with a 38% frequency from experiment II control calves and a 33%
frequency from calves given 25 µg of plasmid DNA per nostril. In contrast,
Corynebacterium spp. were the most frequently isolated organisms in experiment III.
Corynebacterium spp. were isolated with an 83% frequency from experiment III control
calves, a 96% frequency from calves given 50 µg of plasmid DNA per nostril and a 92%
frequency from calves given 100 µg of plasmid DNA per nostril. Bacillus spp.,
Streptococcus spp., and Achromobacter spp. were also frequently isolated from calves in
both experiments.
There were no fluctuations in the average amounts of Gram-positive or Gramnegative bacteria (CFU) isolated from either group in experiment II (Table 4.6, Figures
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4.2 and 4.3). Also, there were no fluctuations in the average amounts of Gram-positive
bacteria (CFU) isolated from any group in experiment III (Table 4.7, Figure 4.4).
However, there were drastic fluctuations in the average amounts of Gram-negative
bacteria (CFU) isolated from all groups in experiment III (Table 4.7, Figure 4.5).
Table 4.6. Mean Gram-positive bacteria, Gram-negative bacteria and M. haemolytica
(CFU) per group isolated from experiment II calves on direct media.
DAY
0

GROUP

3

7

14

1.4x10
2.6x105

3x10
3.9x104

4.3x10
2.2x104

6.5x104
9.3x104

0

4.8x104

1.4x105

3.6x104

6750

7800

2.8x104
Gram (+)
8.2x104
Gram (-)
1.5x104
3.1x104
Mannheimia
0
3.1x104
haemolytica
E25=calves given 25 µg of DNA per nostril

8038
5.3x104

4050
1025

1.8x104
1.4x104

2900
1775

5.3x104

750

8750

0

Colony Forming Units

Controls

4

28

1575
4.8x104

Gram (+)
Gram (-)
Mannheimia
haemolytica

4

21

3.9x10
>9.8x105

E25

5

4

1000000
100000
10000

E25

1000

Controls

100
10
1
0

3

7

14

21

28

DAY

E25=calves given 25 µg of DNA per nostril

Figure 4.2. Mean Gram-positive bacteria per group isolated from experiment II calves
on direct media.
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Colony Forming Units

1000000
100000
10000

E25

1000

Controls

100
10
1
0

3

7

14

21

28

DAY

E25=calves given 25 µg of DNA per nostril

Figure 4.3. Mean Gram-negative bacteria per group isolated from experiment II calves
on direct media.

Table 4.7. Mean Gram-positive bacteria, Gram-negative bacteria and M. haemolytica
(CFU) per group isolated from experiment III calves on direct media.
DAY
0

GROUP
E50

E100

3
4

7
4

14

21

2.4x10
0

1.2x10
750

2x10
4875

8.8x10
1x104

2.5x10
0

4.8x104
0

0

0

0

1x104

0

0

Gram (+)
Gram (-)
Mannheimia
haemolytica

3.3x104
5.3x104

1.1x104
988

2.8x104
1000

1.3x105
7500

1.4x105
0

3.8x105
0

0

0

0

0

0

0

4.3x104
2.5x104

5550
0

6.5x104
0

1.3x105
150

1.7x104

0

0

0

Gram (+)
3.9x104
7.2x104
Gram (-)
0
2488
Mannheimia
0
1250
haemolytica
E50=calves given 50 µg of DNA per nostril
E100=calves given 100 µg of DNA per nostril
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Figure 4.4. Mean Gram-positive bacteria per group isolated from experiment III calves
on direct media.
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Figure 4.5. Mean Gram-negative bacteria per group isolated from experiment III calves
on direct media.
On several days during experiment III no Gram-negative bacteria were isolated. Mean
Gram-negative bacteria colony counts for control calves dropped to 0 at day 14, but
increased slightly by day 28 as seen in figure 4.5. In contrast, mean Gram-negative
bacteria colony counts for calves given 50 µg or 100 µg of plasmid DNA per nostril
dropped to 0 at day 21, and did not increase by day 28 (Figure 4.5).
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In both experiments II and III M. haemolytica 1:A was more often isolated with
Gram-positive bacteria than with Gram-negative bacteria (Table 4.8). M. haemolytica
1:A was isolated with Gram-positive bacteria 84% of the time, while it was isolated with
Gram-negative bacteria only 34% of the time. Corynebacterium spp. were isolated with
M. haemolytica 1:A 11 times (29% frequency). Also, Micrococcus spp. and Bacillus spp.
were isolated with M. haemolytica 1:A 9 times (24% frequency) and 8 times (21%
frequency) respectively.
Table 4.8. Bacteria isolated with M. haemolytica 1:A on both direct and enrichment
media.
Bacteria

Frequency

Frequency
%

None
Achromobacter spp.
Bacillus spp.
Corynebacterium
spp.
Escherichia spp.
Escherichia coli
Gram-negative
coccus
Micrococcus spp.
Staphylococcus spp.
Streptococcus spp.

5
5
8

13%
13%
21%

4
4
3

11
2
4

29%
5%
11%

1
6
5

2
9
1
5

5%
24%
3%
13%

6
2
7
4

Rank

Gram-positive spp.
32
84%
Gram-negative spp.
13
34%
Note: M. haemolytica 1:A was isolated 38 times.

Discussion
The major etiologic agent of bovine pneumonic pasteurellosis is Mannheimia
haemolytica 1:A (Dalgleish, 1990, Frank, 1986), which is believed to be part of the
normal bacterial flora in the URT of clinically healthy cattle; and can exist in the nasal
cavity in very low numbers (Carter et al., 1991, Whiteley et al., 1992). It is believed that
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healthy cattle can carry undetectable levels of M. haemolytica 1:A for long periods of
time (Frank, 1988). M. haemolytica 1:A was not isolated from any calf in either
experiment prior to challenge. The organism is likely carried in one or more sites distinct
from the nasal cavity, specifically the palatine tonsils (Frank et al., 1992). While
remaining in the tonsils, M. haemolytica 1:A is available for stress induced colonization
of the nasal cavity. In these experiments all calves were stressed, after challenge, by
transportation in a crowded trailer, 100 miles for 3 hours. Seven out of the 8 control
calves for the 2 experiments yielded detectible levels of M. haemolytica 1:A in nasal
aspirates throughout the weeks following challenge. Stressed cattle have been shown to
shed larger numbers of the bacterium (Frank et al., 1986). Calves aerosolized with 25 µg
of plasmid DNA per nostril did not gain any protection against M. haemolytica 1:A. All
4 of these calves yielded detectible levels of M. haemolytica 1:A in nasal aspirates.
Furthermore, M. haemolytica 1:A was the most frequently isolated organism from calves
given 25 µg of plasmid DNA per nostril. As early as 1969 it was shown that M.
haemolytica was capable of out numbering the rest of the nasal flora for several days at a
time (Magwood et al., 1969). M. haemolytica 1:A isolated from control calves and calves
given 25 µg of plasmid DNA per nostril also fluctuated in frequency and numbers. Two
of the 4 calves given 50 µg of plasmid DNA per nostril yielded detectible levels of M.
haemolytica 1:A in nasal aspirates following challenge. However, M. haemolytica 1:A
was not detected in any calf given 100 µg of plasmid DNA per nostril at any point during
experiment III. Calves aerosolized with 50 or 100 µg of plasmid DNA per nostril
appeared to gain some or total protection to M. haemolytica 1:A, respectively.
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The nasal passage of cattle is home to a diverse collection of bacteria that make
up the normal and transient flora. These species of bacteria have been found to start
colonizing the URT as early as the calf’s first day of life, and the total bacterial load
increases with age, and under the influence of environmental temperature (Woldehiwet et
al., 1990). Studies have shown that the population of bacteria in the nasal passage of
calves fluctuates heavily in types and numbers (Magwood et al., 1969, Woldehiwet et al.,
1990). Sometimes one genus or species is more dominant than others for random periods
of time. Here, M. haemolytica 1:A was shown to dominate the nasal passages of calves
at several collection days during both experiments. Also, fluctuations in the types and
numbers of bacteria were observed in individual calves. The percent frequency of nasal
flora isolates were different between the summer and fall experiments, but were
consistent among the groups in each experiment. These results indicate that these
organisms were always present at some level, but may have been increased or reduced
due to environmental temperature. Micrococcus spp. were the most frequently isolated
organisms in experiment II control calves. However, Micrococcus spp. were isolated less
frequently than M. haemolytica 1:A from calves given 25 µg of plasmid DNA per nostril.
It is believed that most Micrococcus spp. are heavily circulated in the air, and may not be
able to colonize the nasal mucosa (Magwood et al., 1969). Since they are regularly
isolated from the nasal passage they may still be considered part of the normal flora.
More frequent isolation of Micrococcus spp. during the summer experiments may have
been a result of drier weather. Corynebacterium spp. were isolated from all experiment II
calves, but not as frequently as M. haemolytica 1:A and Micrococcus spp. During the fall
months of experiment III, Corynebacterium spp. were the most frequently isolated
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organism from control calves, calves given 50 µg of plasmid DNA per nostril and calves
given 100 µg of plasmid DNA per nostril. M. haemolytica 1:A and Micrococcus spp.
were isolated less frequently. Bacillus spp. were isolated from calves in both the summer
and fall experiments, although more frequently during the fall experiment. In both
experiments Bacillus spp. were isolated in lower numbers that most other organisms.
Escherichia coli was isolated several times from both groups in experiment II, but was
never isolated during experiment III. Isolation of Escherichia coli may actually be the
result of fecal material in and around the nostrils.
There appeared to be no significant change in the normal bacterial nasal flora.
However, there were drastic fluctuations in the average amounts of Gram-negative
bacteria isolated from all groups in experiment III. Mean Gram-negative bacteria colony
counts for calves given 50 µg or 100 µg of plasmid DNA per nostril dropped late during
the experiment, after which no Gram-negative bacteria were isolated again. Mean Gramnegative bacteria colony counts for control calves also dropped late in the experiment,
after which only small amounts of Gram-negative bacteria were detected. It appeared
that transfecting the nasal passages of cattle may have affected the Gram-negative nasal
flora. However, due to drastic fluctuations in the average amounts of Gram-negative
bacteria isolated from all groups in experiment III, including the control calves,
transfecting the nasal passages of cattle with a gene coding for cecropin B did not
significantly alter the normal indigenous and transient nasal flora.
Bacteria which make up the normal indigenous and transient nasal flora may
enhance or inhibit growth of M. haemolytica. Bacillus isolates were found to inhibit the
growth of M. haemolytica in vitro (Corbeil et al., 1985). In contrast, several Gram-
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positive bacteria such as Micrococcus, Corynebacterium, and Staphylococcus were found
to efficiently enhance the growth of M. haemolytica in vitro (Corbeil et al., 1985). In this
study M. haemolytica 1:A was more often isolated with the Gram-positive bacteria,
specifically Corynebacterium spp. and Micrococcus spp., than with Gram-negative
bacteria. However, Bacillus spp. were isolated with M. haemolytica 1:A, although in low
numbers. Also, it may be important to note that these three groups of bacteria were the
most frequently isolated from all calves in both experiments. Even though studies have
shown that the normal and transient flora of the nasal passage can significantly affect the
colonization of M. haemolytica 1:A (Corbeil et al., 1985), no conclusions could be made
from these results.
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SUMMARY AND CONCLUSIONS

The nasal passages of calves were aerosolized with different amounts of plasmid
DNA containing a gene coding for cecropin B. Results indicate that the cecropin B gene
or cecropin B mRNA expression can be detected in DNA or RNA extracted from nasal
swabs or nasal aspirates. Furthermore, the cecropin B gene could be detected for at least
4 weeks post transfection. Detection of the cecropin B gene prior to calves being
transfected and in untreated control calves could implicate the possible presence of a
native bovine cecropin or cecropin-like gene and is a new finding. Since the detection of
cecropin B DNA in untreated calves could be due to a native bovine cecropin, it is
unclear whether or not levels of cecropin B DNA detected in transfected calves at 4
weeks is a persistence of the transferred gene. Further research may be necessary to
determine the longevity of transfection.
Transfecting calves with 50 or 100 µg of plasmid DNA per nostril provided
sufficient copies the cecropin B gene to transfect areas of the nasal passage. Transfected
areas of the nasal passage expressed cecropin B detectable at the mRNA and peptide
level. Results of these experiments indicate that an aerosol of 25 µg of plasmid DNA per
nostril was not enough to consistently transfect the nasal passage of calves. However,
when compared to the control group cecropin B mRNA expression was significantly
increased in calves given 50 µg or 100 µg of plasmid DNA per nostril at 3 and 7 days
post transfection. When ELISA was used to detect the peptide in nasal aspirates, a
significant increase in mean amounts of cecropin B was observed at day 14 in the two
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groups of calves given 50 µg or 100 µg of plasmid DNA per nostril. No such increase
was observed in the control calves.
Results of this study also indicate that cecropin B is very effective in inhibiting
the virulent challenge strain of Mannheimia haemolytica 1:A in vitro. Growth of this
isolate was inhibited at a concentration of 2 µg/ml. While establishing susceptibility
guidelines was not the goal of this study, these results may warrant further testing with
larger numbers of isolates to accurately determine susceptibility breakpoints for M.
haemolytica 1:A. Although proteolytic enzymes in the bovine nasal mucosa may degrade
the peptide and inhibit antibacterial activity, no inhibition was observed by incubating
cecropin B in bovine nasal secretion. Furthermore, cecropin B was able to completely
inhibit M. haemolytica 1:A growth in BHI broth within 20 minutes of incubation at 37°C.
M. haemolytica 1:A was not isolated from any calf in either experiment prior to
challenge. After challenge, calves were stressed by transportation in a crowded trailer 100
miles for 3 hours. Seven out of the 8 control calves yielded detectible levels of M.
haemolytica 1:A in nasal aspirates throughout the weeks following challenge. Calves
aerosolized with 25 µg of plasmid DNA per nostril did not gain any protection to M.
haemolytica 1:A. All 4 calves given 25 µg of plasmid DNA per nostril yielded detectible
levels of M. haemolytica 1:A in nasal aspirates. Calves aerosolized with 50 or 100 µg of
plasmid DNA per nostril appeared to gain some or total protection to M. haemolytica
1:A, respectively. Two of the 4 calves given 50 µg of plasmid DNA per nostril yielded
detectible levels of M. haemolytica 1:A in nasal aspirates following challenge. However,
M. haemolytica 1:A was not detected in any calf given 100 µg of plasmid DNA per
nostril.
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The percent frequency of nasal flora isolates were different between the summer
(II) and fall (III) experiments, but were consistent between the groups in each
experiment. These results indicate that these organisms were always present at some
level, but may have been increased or reduced due to environmental temperature or
competitive inhibition. There appeared to be no significant change in the normal bacterial
nasal flora. However, there were drastic fluctuations in the average amounts of Gramnegative bacteria isolated from all groups in the fall experiment. Mean Gram-negative
bacteria colony counts for calves given 50 µg or 100 µg of plasmid DNA per nostril
dropped late during the experiment, after which no Gram-negative bacteria were isolated
again. Mean Gram-negative bacteria colony counts for control calves also dropped late
in the experiment, after which only small amounts of Gram-negative bacteria were
detected. It would appear that transfecting the nasal passages of cattle may have affected
the Gram-negative nasal flora. However, due to drastic fluctuations in the average
amounts of Gram-negative bacteria isolated from all groups in the fall experiment,
including the control calves, transfecting the nasal passages of cattle with a gene coding
for cecropin B was not likely responsible for altering the normal nasal flora. While
transfecting the nasal passage of calves with 50 or 100 µg of plasmid DNA per nostril did
appear to inhibit colonization of M. haemolytica 1:A, it did not appear to alter the normal
indigenous and transient flora.
It is beneficial to find new strategies for the control of pneumonic pasteurellosis.
The use of gene therapy will help to eliminate primary M. haemolytica 1:A infection in
cattle destined for the feedlots. The findings here indicate that antimicrobial peptides
such as cecropin B are useful in inhibiting M. haemolytica 1:A colonization. They also
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indicate that the upper respiratory tract may be transfected with genes coding for these
antimicrobial peptides. Transfected calves expressing cecropin B in the nasal passage
exhibited elevated resistance to M. haemolytica 1:A. This work will add important facts
to the database necessary to plan strategies for control of shipping fever.

103

REFERENCES

Biberstein EL, Gills M, Knight H. (1960) Serological types of Pasteurella haemolytica.
Cornell Vet. 60:283-300.
Bland JM, De Lucca AJ, Jacks TJ, Vigo CB. (2001) All-D-cecropin B: synthesis,
conformation, lipopolysaccharide binding, and antibacterial activity. Mol. Cell.
Biochem. 218(1-2):105-111.
Boman HG. (2003) Antibacterial peptides: basic facts and emerging concepts. J. Int.
Med. 254:197-215.
Boman HG, Agerberth B, Boman A. (1993) Mechanisms of action on Escherichia coli
of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun.
60(7):2978-2984.
Boman HG, Faye I, Gudmundson GH, Lee JY, Lidholm DA. (1991) Cell-free immunity
in Cecropia. A model system for antibacterial proteins. Eur. J. Biochem. 201(1):23-31.
Boman HG and Hultmark D. (1987) Cell-free immunity in insects. Ann. Rev.
Microbiol. 41:103-126.
Brennan RE, Corstvet RE, McBride JW. (1997) A simplified method for isolating outer
membrane proteins from Pasteurella haemolytica A1. J. Microbiol. Methods 29:201206.
Brennan RE, Corstvet RE, Paulson DB. (1998) Antibody responses to Pasteurella
haemolytica 1:A and three of its outer membrane proteins in serum, nasal secretions, and
bronchoalveolar lavage fluid from calves. Am. J. Vet. Res. 59(6):727-732.
Briggs RE, Frank GH, Zehr ES. (1998) Development and testing of a unique strain of
Pasteurella haemolytica for use in studies on colonization of the respiratory tract of
cattle. Am. J. Vet. Res. 59(4):426-430.
Buchanan JT, Nickens AD, Cooper RK, Tiersch TR. (2001) Transfection of eastern
oyster (Crassatrea virginica) embryos. Mar. Biotechnol. 3(4):322-335.
Carter GR and Chengappa MM. Lea and Febiger, Malvern PA., (1991) Essentials of
Veterinary Bacteriology and Mycology. 4th Edition. 19:170-176.
Chen HM, Leung KW, Thakur NN, Tan a, Jack RW. (2003) Distinguishing between
different pathways of bilayer disruption by the related antimicrobial peptides cecropin B,
B1 and B3. Eur. J. Biochem. 270(5):911-920.

104

Chen HM, Wang W, Smith D, Chan SC. (1997) Effects of the anti-bacterial peptide
cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer
cells. Biochem. Biophys. Acta 1336(2):171-179.
Chiou PP, Lin CM, Perez L, Chen TT. (2002) Effect of cecropin B and a synthetic
analogue on propagation of fish viruses in vitro. Mar. Biotechnol. 4(3):294-302.
Confer AW, Corstvet RE, Panciera RJ, Rummage JA. (1983) Isolation of Pasteurella
haemolytica and correlation with serum antibody response in clinically normal beef
calves. Vet. Microbiol. 8:601-610.
Confer AW and Panciera RJ. (1994) Testing of two new generation Pasteurella
haemolytica vaccines against experimental bovine pneumonic pasteurellosis. AGRIPractice 15(8):10-15.
Confer AW, Panciera RJ, Fulton RW, Gentry MJ, Rummage JA. (1985) Effect of
vaccination with live or killed Pasteurella haemolytica on resistance to experimental
bovine pneumonic pasteurellosis. Am. J. Vet. Res. 46(2):342-347.
Conlon JA, Shewen PE, Lo RYC. (1991) Efficacy of recombinant leukotoxin in
protection against pneumonic challenge with live Pasteurella haemolytica A1. Infect.
Immun. 59(2):587-591.
Cooper RK. (1998) Transposon-based transformation vectors. Awarded February 17,
1998. U.S. Patent #5,719,055.
Cooper RK and Enright FM. (1996) Transformation of vertebrate cells with lytic
peptide genes. 93A5. Awarded August, 1996. U.S. Patent #5,556,782.
Corbeil LB, Woodward W, Ward AC, Mickelsen WD, Paisley L. (1985) Bacterial
interactions in bovine respiratory and reproductive infections. J. Clin. Microbiol.
21(5):803-807.
Dalgleish R. (1990) Update Bovine pneumonic pasteurellosis. In Practice 12:223-226.
Diamond G, Kaiser V, Rhodes J, Russell JP, Bevins CL. (2000) Transcriptional
regulation of beta-defensin gene expression in tracheal epithelial cells. Infect. Immun.
68(1):113-119.
Duncan JR, Wilkie BN, Hiestand F, Winter AJ. (1972) The serum and secretory
immunoglobulins of cattle: Characterization and quantitation. The Journal of
Immunology 108(4):965-976.
Dunham RA, Warr GW, Nichols A, Duncan PL, Argue B, Middleton D, Kucuktas H.
(2002) Enhanced bacterial disease resistance of transgenic channel catfish Ictalurus
punctatus possessing cecropin genes. Mar. Biotechnol. 4:338-344.

105

Durell SR, Raghunathan G, Guy HR. (1992) Modeling the ion channel structure of
cecropin. Biophys. J. 63(6):1623-1631.
Ferber D. (2003) WHO advises kicking the livestock antibiotic habit. Science
301:1027.
Florack D, Allefs S, Bollen R, Bosch D, Visser B, Stiekema W. (1995) Expression of
giant silkmoth cecropin B genes in tobacco. Transgenic Res. 4(2):132-141
Frank GH. (1986) The role of Pasteurella haemolytica in the bovine respiratory disease
complex. Vet. Med. 81:838-846.
Frank GH. (1988) When Pasteurella haemolytica colonizes the nasal passages of cattle.
Vet. Med. 83:1060-1064.
Frank GH and Briggs RE. (1992) Colonization of the tonsils of calves with Pasteurella
haemolytica. Am. J. Vet. Res. 53(4):481-484.
Frank GH, Briggs RE, Gillette KG. (1986) Colonization of the nasal passages of calves
with Pasteurella haemolytica serotype 1 and regeneration of colonization after
experimentally induced viral infection of the respiratory tract. Am. J. Vet. Res. 47:17041707.
Frank GH, Briggs RE, Loan RW, Purdy CW. (2002) Effects of vaccination prior to
transit and administration of florfenicol at time of arrival in a feedlot on the health of
transported calves and detection of Mannheimia haemolytica in nasal secretions. Am. J.
Vet. Res. 63(2):251-256.
Frank GH, Briggs RE, Loan RW, Purdy CW, Kehr ES. (2000a) Effects of tilmicosin
treatment on Pasteurella haemolytica organisms in nasal secretion specimens of calves
with respiratory tract disease. Am. J. Vet. Res. 61(5):525-529.
Frank GH and Duff GC. (2000b) Effects of tilmicosin phosphate, administered prior to
transport or at time of arrival, and feeding of chlortetracycline, after arrival in a feedlot,
on Mannheimia haemolytica in nasal secretions of transported steers. Am. J. Vet. Res.
61(12):1479-1483.
Giacometti A, Cirioni O, Ghiselli R, Viticchi C, Mocchegiani F, Riva A, Saba V, Scalise
G. (2001) Effect of mono-dose intraperitoneal cecropins in experimental septic shock.
Crit. Care Med. 29(9):1666-1669.
Hagius SD, Reed WA, Fatemi MB, White KL, Enright FM, Elzer PH. (1996). The
brucellacidal activity in transgenic mice expressing a synthetic cecropin-like lytic peptide
or in mice following exogenous peptide treatment. Abst. Annu. Meet. Soc. Microbiol.,
Abst. E46.
Hancock RE and Lehrer R. (1998) Cationic peptides: a new source of antibiotics.
Trends Biotechnol. 16:82-88.

106

Hartman EG and Geryl J (1993) Comparison between the minimal inhibitory
concentration of tilmicosin and oxytetracycline for bovine pneumonic Pasteurella
haemolytica isolates. Veterinary Quarterly 15:184.
Haukland HH and Vorland LH. (2001) Post-antibiotic effect of the antimicrobial peptide
lactoferricin on Escherichia coli and Staphylococcus aureus. J.Antimicrob. Chemother.
48(4):569-571.
Hibbard B, Robb EJ, Chester ST Jr, Dame KJ, Boucher JF, Alaniz GR. (2002) Dose
determination of a long-acting formulation of ceftiofur (ceftiofur crystalline free acid)
administered subcutaneously for the treatment of bovine respiratory disease. J. Vet.
Pharmacol. Ther. 25(3):175-180.
Hultmark D, Engström Å, Bennich H, Kapur, Boman HG. (1982) Insect immunity:
isolation and structure of cecropin D and four minor antibacterial components from
Cecropia pupae. Eur. J. Biochem. 127(1):207-217.
Huttner KM, Brezinski-Caliguri DJ, Mahoney MM, Diamond G. (1998) Antimicrobial
peptide expression is developmentally regulated in the ovine gastrointestinal tract. J.
Nutr. 128(2):297S-299S.
Huttner KM, Lambeth MR, Burkin HR, Burkin DJ, Broad TE. (1998) Localization and
genomic organization of sheep antimicrobial peptide genes. Gene 206(1):85-91.
Johnson KJ, Ward PA, Kunkel RG, Wilson BS. (986) Mediation of IgA induced lung
injury in the Rat: Macrophages and reactive oxygen products. Lab. Invest. 54(5):499506.
Jones EM, Smart A, Bloomberg G, Burgess L, Millar MR. (1994) Lactoferricin, a new
antimicrobial peptide. J. Appl. Bacteriol. 77(2):208-214.
Lee J, Boman A, Chuanxin S, Anderson M, Jörnvall H, Mutt V, Boman HG. (1989)
Antibacterial peptides from pig intestine: Isolation of a mammalian cecropin. Proc. Natl.
Acad. Sci. USA 86:9159-9162.
Lee CW, Shewen PE, Cladman WM, Conlon JAR, Mellors A, Lo RYC. (1994)
Sialoglycoprotease of Pasteurella haemolytica A1: Detection of antisialoglycoprotease
antibodies in sera of calves. Can. J. Vet. Res. 58:93-98.
Lillie LE. (1974) The Bovine Respiratory Disease Complex. Can. Vet. J. 15:233-242.
Magwood SE, Barnum DA, Thomson RG. (1969) Nasal bacterial flora of calves in
healthy and in pneumonia-prone herds. Can. J. Comp. Med. 33(4):237-243.
Marshall SH and Arenas G. (2003) Antimicrobial peptides: A natural alternative to
chemical antibiotics and a potential for applied biotechnology. Elec. J. Biotech. 6(2).

107

McBride JW, Corstvet RE, Paulsen DB, McClure JR, Enright FM. (1996)
Characterization of bovine pulmonary and serum antibody responses after parenteral or
intrapulmonary vaccination with live Pasteurella haemolytica. Comp. Immun. Microbiol.
Infect. Dis. 19(2):99-115.
McBride JW, Wozniak EJ, Brewer AW, Naydan DK, Osburn BI. (1999) Evidence of
Pasteurella haemolytica linked immune complex disease in natural and experimental
models. Microbial Pathogenesis 26:183-193.
Moore AJ, Beazley WD, Bibby MC, Devine DA. (1996) Antimicrobial activity of
cecropins. J. Antimicrob. Chemother. 37(6):1077-1089.
Moore AJ, Loadman PM, Devine DA, Bibby MC. (1995) Extraction of the synthetic
lytic peptide, cecropin B, from biological fluid and analysis using reversed-phase highperformance liquid chromatography. J. Chromatogr. B. Biomed. Appl. 672(2):225-231.
Morck DW, Merrill JK, Gard MS, Olsen ME, Nation PN. (1997) Treatment of
experimentally induced pneumonic pasteurellosis of young calves with tilmicosin. Can.
J. Vet. Res. 61(3):187-192.
Mosier JW, Confer AW, Panciera RJ. (1989) The evolution of vaccines for bovine
pneumonic pasteurellosis. Res. Vet. Sci. 47:1-10.
National Committee for Clinical Laboratory Standards (NCCLS), Villanova, PA. (2001)
Development of in vitro susceptibility testing criteria and quality control parameters, 2nd
ed., Approved guideline M23-A2.
Osusky M, Zhou G, Osuuska L, Hancock RE, Kay WW, Misra S. (2000) Transgenic
plants expressing cationic peptide chimeras exhibit broad-spectrum resistance to
phytopathogens. Nat. Biotechnol. 18(11):1162-1166.
Prescott JF and Yielding. (1990) In vitro susceptibility of selected veterinary bacterial
pathogens to ciprofloxacin, enrofloxacin and norfloxacin. Can. J. Vet. Res. 54:195-197.
Roth JA. (1991) The principles of vaccination: The factors behind vaccine efficacy and
failure. Vet. Med. 406-414.
Sarmasik A, Warr G, Chen TT. (2002) Production of transgenic Medaka with increased
resistance to bacterial pathogens. Mar. Biotechnol. 4:310-322.
SAS Institute Inc., SAS/STAT® User’s Guide, Version 8, Cary, NC: SAS Institute Inc.,
1999. 3884 pp.
Selsted ME, Tang YQ, Morris WL, McGuire PA, Novotny MJ, Smith W, Henschen AH,
Cullor JS. (1996) Purification, primary structure, and antibacterial activities of betadefensins, a new family of antimicrobial peptides from bovine neutrophils. J. Biol.
Chem. 271(27):16430.

108

Sharma A, Sharma R, Imamura M, Yamakawa M, Machii H. (2000) Transgenic
expression of cecropin B, an antibacterial peptide from Bombyx mori, confers enhanced
resistance to bacterial leaf blight in rice. FEBS Lett. 484(1):7-11.
Shewen PE and Wilkie BN. (1982) Cytotoxin of Pasteurella haemolytica acting on
bovine leukocytes. Infect. Immun. 35:91-94.
Shyrock TR, White DW, Staples JM, Werner CS. (1996) Minimum inhibitory
concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for
tilmicosin susceptibility testing against Pasteurella ssp. associated with bovine
respiratory disease. J. Vet. Diagn. Invest. 8:337-344.
Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti M. (1996) Biological
characterization of two novel cathelicidin-derived peptides and identification of structural
requirements for their antimicrobial and cell lytic activities. J. Biol. Chem.
271(45)28375-28381.
Srisailam S, Arunkumar AI, Wang W, Yu C, Chen HM. (2000) Conformational study of
a custom antibacterial peptide cecropin B1: implications of the lytic activity. Biochim.
Biophys. Acta 1479(1-2):275-285.
Steiner H, Andreu D, Merrifield RB. (1988) Binding and action of cecropin and
cecropin analogues: antibacterial peptides from insects. Biochim. Biophys. Acta
939(2):260-266.
Storici P, Tossi A, Lenarcic B, Romeo D. (1996) Purification and structural
characterization of bovine cathelicidins, precursors of antimicrobial peptides. Eur. J.
Biochem. 238(3):769-776.
Vaara M and Vaara T. (1994) Ability of cecropin B to penetrate the enterobacterial
outer membrane. Antimicrob. Agents Chemother. 38(10):2498-2501.
Van Hofsten P, Faye I, Kockum K, Lee JY, Xanthopoulos KG. Boman IA, Boman HG,
Engström Å, Andreu D Merrifield RB. (1985) Molecular cloning, cDNA sequencing,
and chemical synthesis of cecropin B from Hyalophora cecropia. Proc. Natl. Acad. Sci.
82:2240-2243.
Wang W, Smith DK, Chen HM. (1999) The effect of pH on the structure, binding and
model membrane lysis by cecropin B and analogs. Biochim. Biophys. Acta 1473(23):418-430.
Watts JL, Yancey RJ, Salmon SA, Case CA. (1994) A 4-year survey of antimicrobial
susceptibility trends for isolates from cattle with bovine respiratory disease in North
America. J. Clin. Micro. 32(3):725-731.
Whiteley LO, Maheswaran SK, Weiss DJ, Ames TR. (1991) Morphological and
morphometrical analysis of the acute response of the bovine alveolar wall to Pasteurella
haemolytica A1-derived endotoxin and leucotoxin. J. Comp. Path. 104:23-29.
109

Whiteley LO, Maheswaran SK, Weiss DJ, Ames TR, Kannan MS. (1992) Pasteurella
haemolytica A1 and Bovine Respiratory Disease: Pathogenesis. J. Vet. Internal Med.
6:11-22.
Woldehiwet Z, Mamache B, Rowan TG. (1990) The effects of age, environmental
temperature and relative humidity on the bacterial flora of the upper respiratory tract in
calves. Br. Vet. J. 146(3):211-218.
Xanthopoulos KG, Lee JY, Gan R, Kockum K, Faye I, Boman HG. (1988) The structure
of the gene for cecropin B, an antibacterial immune protein from Hyalophora cecropia.
Eur. J. Biochem. 172(2):371-376.
Yates WDG. (1982) A review of infectious bovine rhinotracheitis, shipping fever
pneumonia and viral-bacterial synergism in respiratory disease of cattle. Can. J. Comp.
Med. 46:225-263.
Zhang Q, Tiersch TR, Cooper RK. (1998) Inducible expression of green fluorescent
protein within channel catfish cells by a cecropin gene promoter. Gene 216(1):207-213.

110

APPENDIX A: LETTER OF PERMISSION

111

APPENDIX B: A NOVEL STRATEGY OF CONTROLLING SHIPPING FEVER∗

Bovine pneumonic pasteurellosis or shipping fever continues to be the major
cause of clinical disease and death in feedlot cattle and has been estimated to result in
over a billion dollars in annual losses in the beef cattle industry. Feeder calves from the
southeastern United States normally break with the disease within 30 days after shipment.
The bacteria Mannheimia haemolytica (formerly Pasteurella haemolytica) is the
organism most commonly associated with the disease. There have been numerous
attempts to develop effective vaccines against this disease since the 1950s, but despite
these efforts, a vaccine that provides complete and consistent protection from pneumonic
pasteurellosis in cattle is not available. Most veterinarians rely on antimicrobial agents to
treat the disease. Streptomycin, tetracyclines, β-lactin antibiotics, chloramphenicol,
sulfonamides, and trimethoprim-sulfonamide combinations have all been used to treat
pneumonic pasteurellosis. Ironically studies have shown M. haemolytica to have an
increasing pattern of resistance to all of these antimicrobial agents.
We believe that stressed cattle experience a multiplication of M. haemolytica
bacteria in the upper respiratory tract. Stress usually comes in the form of transportation,
but can include crowding, irregular feeding or watering, abrupt climate changes and
exposure to viral agents or a combination of the above. Multiplication of M.
haemolytica in the upper respiratory tract, especially the nasal cavity, results in
deposition of the bacteria in the lung. This direct lung exposure results in both an
immune and an inflammatory response that interferes with clearance of the bacteria from
the lung and therefore causes pneumonia.
∗
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In the past we have shown that an aerosol vaccination of the upper respiratory
tract resulted in deminished bacterial colonization of M. haemolytica in that area, as well
as prevention of colonization in the lung. Rapid clearance of M. haemolytica was
achieved by stimulating a specific class of secretory antibodies that act at the level of the
mucosal surface of the nasal cavity. The importance of rapid clearance from the nasal
cavity is that there is no longer a source of the organism for continued inhalation into the
lung.
The device used to aerosolize the vaccine into the nasal passage was a siphon feed
gun from a sandblasting system. The gun uses the flow of compressed air to create a
siphon. We modified the gun in order to secure a tube of inoculum to the intake stem.
We also attached a 3-inch piece of rubber tubing to the nozzle of the gun as an extension
to ensure the vaccine was delivered into the nasal passage. A compressed nitrogen
cylinder equipped with a regulator provided the 40-psi needed to aerosolize the vaccine.
Recently, this system was used to deliver a gene encoding an antibacterial protein
called cecropin B. Cecropins were discovered in 1980, when it was noticed that the
Cecropia moth (Hyalophora cecropia) responds to bacterial infection with very effective
antibacterial activity. The pupae synthesize several different classes of antibacterial
proteins, but the more potent of these are the cecropins. Cecropins are small strongly
basic proteins, which have a broad spectrum of bactericidal activity, but are unable to
disrupt mammalian cells. This clearly implicates their possible usefulness as novel
antibiotics.
The cecropin B gene was first incorporated into a DNA vector which also
contained genes encoding for all the enzymes necessary to transfer the cecropin B gene
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into the recipient’s DNA. The plasmid was then complexed to a lipid based transfecting
reagent designed to deliver DNA to the nucleus of mammalian cells. The reagent
complexes with DNA and arranges it in compact structures, to ease entry into the cell.
This reagent also stabilizes the plasmid DNA inside the cell by protecting it from
enzymes meant to destroy foreign DNA. The delivery system for the aerosol was the
modified siphon-feed gun previously described. All personnel involved in the DNA
delivery were protected by wearing disposable coveralls, disposable latex gloves and
HEPA filtered respirators to prevent accidental exposure. The disposable coveralls and
latex gloves were properly disposed as biohazardous waste.
Twenty 300-500 lbs. crossbred beef calves were brought to the LSU Veterinary
Science Farm in Baton Rouge LA and kept on pasture. Calves were randomly assigned
to 5 groups with 4 calves in each group. Three groups were designated the experimental
groups, and the other two were designated the control groups. The 5 groups remained
isolated throughout the experiment. Each of the experimental calves were given
incremented amounts of DNA suspended in 3 ml of sterile Phosphate buffered saline (pH
7.2) per nostril, aerosolized with 40-psi of pressure. Control calves were aerosolized
first, without DNA, then allowed to return to the pasture. The experimental calves were
aerosolized one at a time, with that calf being the only calf allowed in the chute at the
time. All 20 (experimental and control) calves were challenged intranasally with a
virulent strain of M. haemolytica suspended in 3 ml of sterile Phosphate buffered saline
(pH 7.2) per nostril. Following the inoculation, all calves were trucked separately (by
groups) 100 miles for 3 hours to stress them. Nasal swabs were collected on days 0, 3, 7,
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14, 21 and 28. Samples were submitted for bacterial culture. Day 0 samples were
collected prior to any treatment.
M. haemolytica was not isolated from any calf at day 0. However, after challenge
M. haemolytica was isolated from 7 of 8 control calves at some point during the
experiment. M. haemolytica was isolated from 4 of 8 control calves at day 3, and 5 of 8
calves from days 7 thru 28. M. haemolytica was isolated from all 4 calves given 25µg of
DNA per nostril at day 3. M. haemolytica was also isolated from all 4 of these calves on
days 7, 14, 21 or 28. M. haemolytica was isolated from only 1 of 4 calves given 50µg of
DNA per nostril at day 3, and only 1 of 4 calves from days 7 thru 28. M. haemolytica
was not isolated from any of the 4 calves given 100µg of DNA per nostril at any point of
the experiment.
Table B.1. Summary of Mannheimia haemolytica isolated
GROUP

Day 0

Day 3

Day 7-28

TOTAL

Controls

0 of 4

4 of 8

5 of 8

7 of 8

E25

0 of 4

4 of 4

4 of 4

4 of 4

E50

0 of 4

1 of 4

1 of 4

2 of 4

E100 0 of 4 0 of 4
0 of 4
0 of 4
E25, Calves given 25 ug/ml of DNA per nostril
E50, Calves given 50 ug/ml of DNA per nostril
E100, Calves given 100 ug/ml of DNA per nostril

It is beneficial to find novel strategies for the control of pneumonic pasteurellosis.
The findings indicate that novel antimicrobial proteins such as cecropin B may be useful
in inhibiting M. haemolytica colonization. They also indicate that the upper respiratory
tract may be transfected with the genes coding for these novel antimicrobial proteins.
Transfecting the nasal passage of calves with sufficient copies of the cecropin B gene was
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shown to inhibit colonization of M. haemolytica. Inoculating calves with 100µg of
plasmid DNA per nostril completely inhibited M. haemolytica colonization. Inoculating
calves with 50µg of plasmid DNA per nostril provided some resistance to M. haemolytica
when compared to control calves. However, inoculating calves with 25µg of plasmid
DNA per nostril provided little or no resistance to M. haemolytica when compared to
control calves. This work will add important facts to the database necessary to plan
strategies for control of shipping fever.

116

VITA
Charles Mitchell Boudreaux is the son of Kenneth P. Boudreaux and Annabelle L.
Boudreaux from New Iberia, Louisiana. He was born on March 18,1974, in New Iberia,
Louisiana. He attended Avery Island Elementary for grades one through six, New Iberia
Middle School for grades seven and eight, and graduated from New Iberia Senior High in
1992. While in high school he was an active member of the 4-H Club, participating in
livestock exhibition, livestock judging, entomology, and leadership programs. In the
spring of 1998 he graduated from Louisiana State University in Baton Rouge with a
Bachelor’s degree in animal sciences. Following graduation he took a position as a
research associate in the Department of Veterinary Science with Dr. Richard Corstvet. In
the fall of 2001 he began working on a master of science degree in Veterinary Medical
Sciences under the direction of Dr. Richard Corstvet. Charles is now a candidate for his
master of science degree in Veterinary Medical Sciences through the Department of
Pathobiological Sciences, Louisiana State University, School of Veterinary Medicine.

117

